<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:07:12Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9305188" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9305188</identifier>
        <datestamp>2022-07-28</datestamp>
        <setSpec>blackwellopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="fsb222173" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">FASEB J</journal-id>
              <journal-id journal-id-type="iso-abbrev">FASEB J</journal-id>
              <journal-id journal-id-type="doi">10.1096/(ISSN)1530-6860</journal-id>
              <journal-id journal-id-type="publisher-id">FSB2</journal-id>
              <journal-title-group>
                <journal-title>The FASEB Journal</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0892-6638</issn>
              <issn pub-type="epub">1530-6860</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9305188</article-id>
              <article-id pub-id-type="pmcid">PMC9305188</article-id>
              <article-id pub-id-type="pmc-uid">9305188</article-id>
              <article-id pub-id-type="pmid">35104001</article-id>
              <article-id pub-id-type="pmid">35104001</article-id>
              <article-id pub-id-type="doi">10.1096/fj.202101219RR</article-id>
              <article-id pub-id-type="publisher-id">FSB222173</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Research Articles</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Lipoxins modulate neutrophil oxidative burst, integrin expression and lymphatic transmigration differentially in human health and atherosclerosis</article-title>
                <alt-title alt-title-type="left-running-head">KRAFT et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="fsb222173-cr-0001" contrib-type="author">
                  <name>
                    <surname>Kraft</surname>
                    <given-names>Jamie D.</given-names>
                  </name>
                  <xref rid="fsb222173-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="fsb222173-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="fsb222173-cr-0002" contrib-type="author">
                  <name>
                    <surname>Blomgran</surname>
                    <given-names>Robert</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2767-8175</contrib-id>
                  <xref rid="fsb222173-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="fsb222173-cr-0003" contrib-type="author">
                  <name>
                    <surname>Bergström</surname>
                    <given-names>Ida</given-names>
                  </name>
                  <xref rid="fsb222173-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="fsb222173-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="fsb222173-cr-0004" contrib-type="author">
                  <name>
                    <surname>Soták</surname>
                    <given-names>Matúš</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9984-9340</contrib-id>
                  <xref rid="fsb222173-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="fsb222173-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="fsb222173-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="fsb222173-cr-0005" contrib-type="author">
                  <name>
                    <surname>Clark</surname>
                    <given-names>Madison</given-names>
                  </name>
                  <xref rid="fsb222173-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="fsb222173-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="fsb222173-cr-0006" contrib-type="author">
                  <name>
                    <surname>Rani</surname>
                    <given-names>Alankrita</given-names>
                  </name>
                  <xref rid="fsb222173-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="fsb222173-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="fsb222173-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="fsb222173-cr-0007" contrib-type="author">
                  <name>
                    <surname>Rajan</surname>
                    <given-names>Meenu Rohini</given-names>
                  </name>
                  <xref rid="fsb222173-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="fsb222173-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="fsb222173-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="fsb222173-cr-0008" contrib-type="author">
                  <name>
                    <surname>Dalli</surname>
                    <given-names>Jesmond</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6328-3640</contrib-id>
                  <xref rid="fsb222173-aff-0007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                  <xref rid="fsb222173-aff-0008" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib id="fsb222173-cr-0009" contrib-type="author">
                  <name>
                    <surname>Nyström</surname>
                    <given-names>Sofia</given-names>
                  </name>
                  <xref rid="fsb222173-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="fsb222173-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="fsb222173-cr-0010" contrib-type="author">
                  <name>
                    <surname>Quiding‐Järbrink</surname>
                    <given-names>Marianne</given-names>
                  </name>
                  <xref rid="fsb222173-aff-0009" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib id="fsb222173-cr-0011" contrib-type="author">
                  <name>
                    <surname>Bromberg</surname>
                    <given-names>Jonathan</given-names>
                  </name>
                  <xref rid="fsb222173-aff-0010" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                  <xref rid="fsb222173-aff-0011" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                  <xref rid="fsb222173-aff-0012" ref-type="aff">
                    <sup>12</sup>
                  </xref>
                  <xref rid="fsb222173-aff-0013" ref-type="aff">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib id="fsb222173-cr-0012" contrib-type="author">
                  <name>
                    <surname>Skoog</surname>
                    <given-names>Per</given-names>
                  </name>
                  <xref rid="fsb222173-aff-0014" ref-type="aff">
                    <sup>14</sup>
                  </xref>
                  <xref rid="fsb222173-aff-0015" ref-type="aff">
                    <sup>15</sup>
                  </xref>
                </contrib>
                <contrib id="fsb222173-cr-0013" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Börgeson</surname>
                    <given-names>Emma</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2290-9472</contrib-id>
                  <xref rid="fsb222173-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="fsb222173-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="fsb222173-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <address>
                    <email>emma.borgeson@wlab.gu.se</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="fsb222173-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Department of Molecular and Clinical Medicine</named-content>
                <named-content content-type="organisation-division">Wallenberg Laboratory</named-content>
                <named-content content-type="organisation-division">Institute of Medicine</named-content>
                <institution>Sahlgrenska Academy</institution>
                <institution>University of Gothenburg</institution>
                <city>Gothenburg</city>
                <country country="SE">Sweden</country>
              </aff>
              <aff id="fsb222173-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Wallenberg Centre for Molecular and Translational Medicine</named-content>
                <institution>University of Gothenburg</institution>
                <city>Gothenburg</city>
                <country country="SE">Sweden</country>
              </aff>
              <aff id="fsb222173-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Division of Inflammation and Infection</named-content>
                <named-content content-type="organisation-division">Department of Biomedical and Clinical Sciences</named-content>
                <named-content content-type="organisation-division">Faculty of Medicine and Health Sciences</named-content>
                <institution>Linköping University</institution>
                <city>Linköping</city>
                <country country="SE">Sweden</country>
              </aff>
              <aff id="fsb222173-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Department of Clinical Immunology and Transfusion Medicine</named-content>
                <institution>Linköping University</institution>
                <city>Linköping</city>
                <country country="SE">Sweden</country>
              </aff>
              <aff id="fsb222173-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Department of Biomedical and Clinical Sciences</named-content>
                <institution>Linköping University</institution>
                <city>Linköping</city>
                <country country="SE">Sweden</country>
              </aff>
              <aff id="fsb222173-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <named-content content-type="organisation-division">Department of Clinical Physiology</named-content>
                <institution>Region Vaestra Goetaland</institution>
                <institution>Sahlgrenska University Hospital</institution>
                <city>Gothenburg</city>
                <country country="SE">Sweden</country>
              </aff>
              <aff id="fsb222173-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <named-content content-type="organisation-division">William Harvey Research Institute</named-content>
                <named-content content-type="organisation-division">Barts &amp; The London School of Medicine &amp; Dentistry</named-content>
                <institution>Queen Mary University of London</institution>
                <city>London</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="fsb222173-aff-0008">
                <label>
                  <sup>8</sup>
                </label>
                <named-content content-type="organisation-division">Centre for Inflammation and Therapeutic Innovation</named-content>
                <institution>Queen Mary University of London</institution>
                <city>London</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="fsb222173-aff-0009">
                <label>
                  <sup>9</sup>
                </label>
                <named-content content-type="organisation-division">Department of Microbiology and Immunology</named-content>
                <named-content content-type="organisation-division">Institute of Biomedicine</named-content>
                <institution>Sahlgrenska Academy</institution>
                <institution>University of Gothenburg</institution>
                <city>Gothenburg</city>
                <country country="SE">Sweden</country>
              </aff>
              <aff id="fsb222173-aff-0010">
                <label>
                  <sup>10</sup>
                </label>
                <named-content content-type="organisation-division">Department of Surgery</named-content>
                <institution>University of Maryland School of Medicine</institution>
                <city>Baltimore</city>
                <named-content content-type="country-part">Maryland</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="fsb222173-aff-0011">
                <label>
                  <sup>11</sup>
                </label>
                <named-content content-type="organisation-division">Department of Microbiology and Immunology</named-content>
                <institution>University of Maryland School of Medicine</institution>
                <city>Baltimore</city>
                <named-content content-type="country-part">Maryland</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="fsb222173-aff-0012">
                <label>
                  <sup>12</sup>
                </label>
                <named-content content-type="organisation-division">Center for Vascular and Inflammatory Diseases</named-content>
                <institution>University of Maryland School of Medicine</institution>
                <city>Baltimore</city>
                <named-content content-type="country-part">Maryland</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="fsb222173-aff-0013">
                <label>
                  <sup>13</sup>
                </label>
                <named-content content-type="organisation-division">Marlene and Stewart Greenebaum Comprehensive Cancer Center</named-content>
                <institution>University of Maryland</institution>
                <city>Baltimore</city>
                <named-content content-type="country-part">Maryland</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="fsb222173-aff-0014">
                <label>
                  <sup>14</sup>
                </label>
                <named-content content-type="organisation-division">Department of Vascular Surgery and Institute of Medicine</named-content>
                <institution>Sahlgrenska University Hospital and Academy</institution>
                <city>Gothenburg</city>
                <country country="SE">Sweden</country>
              </aff>
              <aff id="fsb222173-aff-0015">
                <label>
                  <sup>15</sup>
                </label>
                <named-content content-type="organisation-division">Department of Molecular and Clinical Medicine</named-content>
                <institution>Sahlgrenska University Hospital and Academy</institution>
                <city>Gothenburg</city>
                <country country="SE">Sweden</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Emma Börgeson, Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg 40530, Sweden.<break/>
Email: <email>emma.borgeson@wlab.gu.se</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>01</day>
                <month>2</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>3</month>
                <year>2022</year>
              </pub-date>
              <volume>36</volume>
              <issue seq="50">3</issue>
              <issue-id pub-id-type="doi">10.1096/fsb2.v36.3</issue-id>
              <elocation-id>e22173</elocation-id>
              <history>
                <date date-type="rev-recd">
                  <day>04</day>
                  <month>1</month>
                  <year>2022</year>
                </date>
                <date date-type="received">
                  <day>30</day>
                  <month>7</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>10</day>
                  <month>1</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2022 Federation of American Societies for Experimental Biology-->
                <copyright-statement content-type="article-copyright">© 2022 The Authors. <italic toggle="yes">The FASEB Journal</italic> published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:FSB2-36-0.pdf"/>
              <abstract id="fsb222173-abs-0001">
                <title>Abstract</title>
                <p>Dysregulated chronic inflammation plays a crucial role in the pathophysiology of atherosclerosis and may be a result of impaired resolution. Thus, restoring levels of specialized pro‐resolving mediators (SPMs) to promote the resolution of inflammation has been proposed as a therapeutic strategy for patients with atherosclerosis, in addition to standard clinical care. Herein, we evaluated the effects of the SPM lipids, lipoxin A<sub>4</sub> (LXA<sub>4</sub>) and lipoxin B<sub>4</sub> (LXB<sub>4</sub>), on neutrophils isolated from patients with atherosclerosis compared with healthy controls. Patients displayed altered endogenous SPM production, and we demonstrated that lipoxin treatment in whole blood from atherosclerosis patients attenuates neutrophil oxidative burst, a key contributor to atherosclerotic development. We found the opposite effect in neutrophils from healthy controls, indicating a potential mechanism whereby lipoxins aid the endogenous neutrophil function in health but reduce its excessive activation in disease. We also demonstrated that lipoxins attenuated upregulation of the high‐affinity conformation of the CD11b/CD18 integrin, which plays a central role in clot activation and atherosclerosis. Finally, LXB<sub>4</sub> enhanced lymphatic transmigration of human neutrophils isolated from patients with atherosclerosis. This finding is noteworthy, as impaired lymphatic function is now recognized as an important contributor to atherosclerosis. Although both lipoxins modulated neutrophil function, LXB<sub>4</sub> displayed more potent effects than LXA<sub>4</sub> in humans. This study highlights the therapeutic potential of lipoxins in atherosclerotic disease and demonstrates that the effect of these SPMs may be specifically tailored to the need of the individual.</p>
              </abstract>
              <kwd-group>
                <kwd id="fsb222173-kwd-0001">atherosclerosis</kwd>
                <kwd id="fsb222173-kwd-0002">cardiovascular disease</kwd>
                <kwd id="fsb222173-kwd-0003">CD11b/CD18 integrin</kwd>
                <kwd id="fsb222173-kwd-0004">lipoxins</kwd>
                <kwd id="fsb222173-kwd-0005">lymphatics transmigration</kwd>
                <kwd id="fsb222173-kwd-0006">neutrophils</kwd>
                <kwd id="fsb222173-kwd-0007">reactive oxygen species</kwd>
                <kwd id="fsb222173-kwd-0008">resolution of inflammation</kwd>
                <kwd id="fsb222173-kwd-0009">specialized pro‐resolving mediators</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>Vetenskapsrådet (VR)
</institution>
                      <institution-id institution-id-type="doi">10.13039/501100004359</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>2016/82</award-id>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>
                    <institution-wrap>
                      <institution>Svenska Sällskapet för Medicinsk Forskning (SSMF)
</institution>
                      <institution-id institution-id-type="doi">10.13039/501100003748</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>S150086</award-id>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>
                    <institution-wrap>
                      <institution>EC | H2020 | H2020 Priority Excellent Science | H2020 European Research Council (ERC)
</institution>
                      <institution-id institution-id-type="doi">10.13039/100010663</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>804418</award-id>
                </award-group>
                <award-group id="funding-0004">
                  <funding-source>
                    <institution-wrap>
                      <institution>Knut och Alice Wallenbergs Stiftelse (Knut and Alice Wallenberg Foundation)
</institution>
                      <institution-id institution-id-type="doi">10.13039/501100004063</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="5"/>
                <table-count count="2"/>
                <page-count count="20"/>
                <word-count count="11385"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>March 2022</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.7 mode:remove_FC converted:21.07.2022</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="fsb222173-cit-1001"><string-name><surname>Kraft</surname><given-names>JD</given-names></string-name>, <string-name><surname>Blomgran</surname><given-names>R</given-names></string-name>, <string-name><surname>Bergström</surname><given-names>I</given-names></string-name>, et al. <article-title>Lipoxins modulate neutrophil oxidative burst, integrin expression and lymphatic transmigration differentially in human health and atherosclerosis</article-title>. <source>FASEB J</source>. <year>2022</year>;<volume>36</volume>:<elocation-id>e22173</elocation-id>. doi:<pub-id pub-id-type="doi">10.1096/fj.202101219RR</pub-id><pub-id pub-id-type="pmid">35104001</pub-id></mixed-citation>
              </p>
            </notes>
          </front>
          <body id="fsb222173-body-0001">
            <def-list list-content="abbreviations" id="fsb222173-lp-0001">
              <title>Abbreviations</title>
              <def-item>
                <term>DHR</term>
                <def>
                  <p>dihydrorhodamine 123</p>
                </def>
              </def-item>
              <def-item>
                <term>
                  <italic toggle="yes">E. coli</italic>
                </term>
                <def>
                  <p>
                    <italic toggle="yes">Escherichia coli</italic>
                  </p>
                </def>
              </def-item>
              <def-item>
                <term>fMLP</term>
                <def>
                  <p>N‐formyl‐Met‐Leu‐Phe</p>
                </def>
              </def-item>
              <def-item>
                <term>IL‐8</term>
                <def>
                  <p>interleukin‐8</p>
                </def>
              </def-item>
              <def-item>
                <term>LEC</term>
                <def>
                  <p>lymphatic endothelial cell</p>
                </def>
              </def-item>
              <def-item>
                <term>LXA<sub>4</sub>
</term>
                <def>
                  <p>lipoxin A4 [5(S),6(R),15(S)‐trihydroxy‐7E,9E,11Z,13E‐eicosatetraenoic acid]</p>
                </def>
              </def-item>
              <def-item>
                <term>LXB<sub>4</sub>
</term>
                <def>
                  <p>lipoxin B4 [5(S),14(R),15(S)‐trihydroxy‐6E,8Z,10E,12E‐eicosatetraenoic acid]</p>
                </def>
              </def-item>
              <def-item>
                <term>MFI</term>
                <def>
                  <p>mean fluorescence intensity</p>
                </def>
              </def-item>
              <def-item>
                <term>PBS</term>
                <def>
                  <p>phosphate‐buffered saline</p>
                </def>
              </def-item>
              <def-item>
                <term>PMA</term>
                <def>
                  <p>phorbol 12‐myristate 13‐acetate</p>
                </def>
              </def-item>
              <def-item>
                <term>ROS</term>
                <def>
                  <p>reactive oxygen species</p>
                </def>
              </def-item>
              <def-item>
                <term>SPMs</term>
                <def>
                  <p>specialized pro‐resolving mediators</p>
                </def>
              </def-item>
              <def-item>
                <term>TNF‐α</term>
                <def>
                  <p>tumor necrosis factor‐α</p>
                </def>
              </def-item>
            </def-list>
            <sec id="fsb222173-sec-0001">
              <label>1</label>
              <title>INTRODUCTION</title>
              <p>Dysregulated chronic inflammation is widely recognized to play a crucial role in the pathophysiology of atherosclerosis and cardiovascular disease.<xref rid="fsb222173-bib-0001" ref-type="bibr"><sup>1</sup></xref>, <xref rid="fsb222173-bib-0002" ref-type="bibr"><sup>2</sup></xref> Evidence suggests that the chronic inflammation observed within atherosclerotic lesions may result from a failure to induce the resolution of inflammation.<xref rid="fsb222173-bib-0003" ref-type="bibr"><sup>3</sup></xref> Thus, restoring levels of specialized pro‐resolving mediators (SPMs) to promote the resolution of inflammation is emerging as a potential anti‐atherogenic therapeutic strategy, in addition to standard clinical care.<xref rid="fsb222173-bib-0004" ref-type="bibr"><sup>4</sup></xref>
</p>
              <p>In healthy individuals, inflammation consists of two phases; the initial acute phase, followed by the resolving phase.<xref rid="fsb222173-bib-0005" ref-type="bibr"><sup>5</sup></xref> The latter phase is orchestrated by SPMs derived from either omega‐3 fatty acids (eicosapentaenoic acid or docosahexaenoic acid) or omega‐6 fatty acids (arachidonic acid).<xref rid="fsb222173-bib-0005" ref-type="bibr"><sup>5</sup></xref>, <xref rid="fsb222173-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="fsb222173-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="fsb222173-bib-0008" ref-type="bibr"><sup>8</sup></xref> SPMs exert their pro‐resolving effects through various mechanisms, including regulating transcription factors, cytokine release, receptor expression, immune cell migration, and modulating cell phenotype, among others.<xref rid="fsb222173-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="fsb222173-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="fsb222173-bib-0011" ref-type="bibr"><sup>11</sup></xref>, <xref rid="fsb222173-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="fsb222173-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="fsb222173-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="fsb222173-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="fsb222173-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="fsb222173-bib-0017" ref-type="bibr"><sup>17</sup></xref> An ample body of evidence demonstrates that promoting the resolution of inflammation in atherosclerosis through the therapeutic application of SPMs has beneficial effects. Atherosclerotic animal models demonstrate that treatment with SPMs or peptides binding to their receptors attenuates atherosclerotic development, decreases intimal hyperplasia, and increases plaque stability.<xref rid="fsb222173-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="fsb222173-bib-0019" ref-type="bibr"><sup>19</sup></xref>, <xref rid="fsb222173-bib-0020" ref-type="bibr"><sup>20</sup></xref>, <xref rid="fsb222173-bib-0021" ref-type="bibr"><sup>21</sup></xref>, <xref rid="fsb222173-bib-0022" ref-type="bibr"><sup>22</sup></xref>, <xref rid="fsb222173-bib-0023" ref-type="bibr"><sup>23</sup></xref>, <xref rid="fsb222173-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="fsb222173-bib-0025" ref-type="bibr"><sup>25</sup></xref>, <xref rid="fsb222173-bib-0026" ref-type="bibr"><sup>26</sup></xref>, <xref rid="fsb222173-bib-0027" ref-type="bibr"><sup>27</sup></xref> For instance, the omega‐6‐derived lipid mediator, lipoxin A<sub>4</sub> (LXA<sub>4</sub>), significantly reduces atherosclerotic lesions in the aortic arch of mice.<xref rid="fsb222173-bib-0028" ref-type="bibr"><sup>28</sup></xref> Interestingly, in humans, an imbalance of the ratio between pro‐resolving and pro‐inflammatory lipid mediators indicates more severe plaque phenotypes<xref rid="fsb222173-bib-0018" ref-type="bibr"><sup>18</sup></xref> and increased intima media thickness.<xref rid="fsb222173-bib-0029" ref-type="bibr"><sup>29</sup></xref> Recent evidence also suggests that the anti‐atherogenic therapeutic potential of SPMs may translate from experimental models to humans. For example, we have previously demonstrated that LXA<sub>4</sub> treatment attenuates human blood clot formation by manipulating neutrophil integrin activation.<xref rid="fsb222173-bib-0010" ref-type="bibr"><sup>10</sup></xref> In addition, ex vivo treatment of human carotid plaques with LXA<sub>4</sub> attenuates inflammation through inhibition of pro‐inflammatory cytokine release.<xref rid="fsb222173-bib-0028" ref-type="bibr"><sup>28</sup></xref> Together, these findings provide a solid foundation to continue to explore the role of lipoxins in resolving chronic inflammation in atherosclerosis.</p>
              <p>Here, we continued to investigate the therapeutic effect of lipoxins in human atherosclerosis. We studied cellular responses in patients with atherosclerosis and healthy controls, as SPM treatment may elicit varied responses in health versus disease. We used an ex vivo treatment model of neutrophils from atherosclerosis patients and healthy volunteers, as these cells play an important role in creating a pro‐atherogenic environment.<xref rid="fsb222173-bib-0030" ref-type="bibr"><sup>30</sup></xref>, <xref rid="fsb222173-bib-0031" ref-type="bibr"><sup>31</sup></xref>, <xref rid="fsb222173-bib-0032" ref-type="bibr"><sup>32</sup></xref>, <xref rid="fsb222173-bib-0033" ref-type="bibr"><sup>33</sup></xref>, <xref rid="fsb222173-bib-0034" ref-type="bibr"><sup>34</sup></xref>, <xref rid="fsb222173-bib-0035" ref-type="bibr"><sup>35</sup></xref> We found that lipoxins modify reactive oxygen species (ROS) production, integrin receptor expression, and lymphatic migration of neutrophils isolated from patients with atherosclerosis. Additionally, some of these mechanisms are differentially regulated by the lipoxins in health versus disease.</p>
            </sec>
            <sec sec-type="materials-and-methods" id="fsb222173-sec-0002">
              <label>2</label>
              <title>MATERIALS AND METHODS</title>
              <sec id="fsb222173-sec-0003">
                <label>2.1</label>
                <title>Patient recruitment</title>
                <p>We included patients with peripheral artery disease and concomitant advanced atherosclerosis (<italic toggle="yes">n</italic> = 10) scheduled to undergo vascular surgery for revascularization, as stated in Table <xref rid="fsb222173-tbl-0001" ref-type="table">1</xref>. We also included a control group consisting of reportedly healthy volunteers without diagnosed or treated diabetes, hypertension, or hyperlipidemia (<italic toggle="yes">n</italic> = 10). Given the nature of the atherosclerotic disease, the patient group consisted of older individuals (75.1 ± 1.5 years). Therefore, the inclusion criteria for the control group stated that healthy volunteers must be more than 50 years old to minimize the confounding effects of “inflammaging”.<xref rid="fsb222173-bib-0036" ref-type="bibr"><sup>36</sup></xref> Study participants underwent a detailed medical history and a health exam measuring blood pressure, height, weight, sagittal height, and body temperature before donating blood. Patients in drug trials or who were deemed unable to adequately comprehend the informed consent were excluded from the recruitment process. All study participants were enrolled in accordance with the Helsinki Declaration and provided written informed consent. The study was approved by the Swedish Ethical Review Authority #Dnr 660‐18 (<ext-link xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> NCT03732612).</p>
                <table-wrap position="float" id="fsb222173-tbl-0001" content-type="TABLE">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Clinical characteristics of control and patient cohorts</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Variables</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Controls</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Patients with atherosclerosis</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic>‐Value</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Significance</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Cohort characteristics</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1"><italic toggle="yes">n</italic> (%)</td>
                        <td align="left" rowspan="1" colspan="1">10</td>
                        <td align="left" rowspan="1" colspan="1">10</td>
                        <td align="left" rowspan="1" colspan="1">N/A</td>
                        <td align="left" rowspan="1" colspan="1">N/A</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Sex</td>
                        <td align="left" rowspan="1" colspan="1">1 ♂/9 ♀</td>
                        <td align="left" rowspan="1" colspan="1">5 ♂/5 ♀</td>
                        <td align="left" rowspan="1" colspan="1">.1409</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age (years)</td>
                        <td align="left" rowspan="1" colspan="1">59.6 ± 4.88</td>
                        <td align="left" rowspan="1" colspan="1">75.1 ± 4.84</td>
                        <td align="left" rowspan="1" colspan="1">.0002</td>
                        <td align="left" rowspan="1" colspan="1">***</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Body temperature (°C)</td>
                        <td align="left" rowspan="1" colspan="1">36.5 ± 0.25</td>
                        <td align="left" rowspan="1" colspan="1">36.45 ± 0.35</td>
                        <td align="left" rowspan="1" colspan="1">&gt;.999</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Anthropometrics</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Weight (kg)</td>
                        <td align="left" rowspan="1" colspan="1">63.87 ± 5.35</td>
                        <td align="left" rowspan="1" colspan="1">77.7 ± 17.93</td>
                        <td align="left" rowspan="1" colspan="1">.0342</td>
                        <td align="left" rowspan="1" colspan="1">*</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Body mass index (BMI, kg/m<sup>2</sup>)</td>
                        <td align="left" rowspan="1" colspan="1">22.34 ± 1.64</td>
                        <td align="left" rowspan="1" colspan="1">25.8 ± 4.90</td>
                        <td align="left" rowspan="1" colspan="1">.0686</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Height (cm)</td>
                        <td align="left" rowspan="1" colspan="1">169.3 ± 6.20</td>
                        <td align="left" rowspan="1" colspan="1">173.1 ± 7.72</td>
                        <td align="left" rowspan="1" colspan="1">.3840</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Waist circumference (cm)</td>
                        <td align="left" rowspan="1" colspan="1">79.9 ± 5.77</td>
                        <td align="left" rowspan="1" colspan="1">101.8 ± 15.62</td>
                        <td align="left" rowspan="1" colspan="1">.0028</td>
                        <td align="left" rowspan="1" colspan="1">**</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Waist‐to‐height ratio (%)</td>
                        <td align="left" rowspan="1" colspan="1">0.47 ± 0.04</td>
                        <td align="left" rowspan="1" colspan="1">0.59 ± 0.09</td>
                        <td align="left" rowspan="1" colspan="1">.0032</td>
                        <td align="left" rowspan="1" colspan="1">**</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Sagittal height (cm)</td>
                        <td align="left" rowspan="1" colspan="1">16.67 ± 2.07</td>
                        <td align="left" rowspan="1" colspan="1">23.35 ± 4.29</td>
                        <td align="left" rowspan="1" colspan="1">.0013</td>
                        <td align="left" rowspan="1" colspan="1">**</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Surgical indication</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aneurism indication with concomitant atherosclerosis (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">N/A</td>
                        <td align="left" rowspan="1" colspan="1">0/10 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">N/A</td>
                        <td align="left" rowspan="1" colspan="1">N/A</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aortoiliac disease (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">N/A</td>
                        <td align="left" rowspan="1" colspan="1">1/10 (10%)</td>
                        <td align="left" rowspan="1" colspan="1">N/A</td>
                        <td align="left" rowspan="1" colspan="1">N/A</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Critical limb ischemia (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">N/A</td>
                        <td align="left" rowspan="1" colspan="1">3/10 (30%)</td>
                        <td align="left" rowspan="1" colspan="1">N/A</td>
                        <td align="left" rowspan="1" colspan="1">N/A</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Claudication (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">N/A</td>
                        <td align="left" rowspan="1" colspan="1">6/10 (60%)</td>
                        <td align="left" rowspan="1" colspan="1">N/A</td>
                        <td align="left" rowspan="1" colspan="1">N/A</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Risk factors cardiovascular disease</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diagnosed hypertension (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">0/10 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">8/10 (80%)</td>
                        <td align="left" rowspan="1" colspan="1">.0007</td>
                        <td align="left" rowspan="1" colspan="1">***</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diagnosed diabetes (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">0/10 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">1/10 (10%)</td>
                        <td align="left" rowspan="1" colspan="1">&gt;.999</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">High low‐density lipoprotein (LDL)‐Cholesterol (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">1/10 (10%)</td>
                        <td align="left" rowspan="1" colspan="1">0/10 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">&gt;.999</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Low high‐density lipoprotein (HDL)‐Cholesterol (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">0/10 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">5/10 (50%)</td>
                        <td align="left" rowspan="1" colspan="1">.0325</td>
                        <td align="left" rowspan="1" colspan="1">*</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hyperlipidemia (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">1/10 (10%)</td>
                        <td align="left" rowspan="1" colspan="1">9/10 (90%)</td>
                        <td align="left" rowspan="1" colspan="1">.0011</td>
                        <td align="left" rowspan="1" colspan="1">**</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aorta iliac atherosclerosis (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">N/A</td>
                        <td align="left" rowspan="1" colspan="1">6/10 (60%)</td>
                        <td align="left" rowspan="1" colspan="1">N/A</td>
                        <td align="left" rowspan="1" colspan="1">N/A</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Peripheral atherosclerosis (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">N/A</td>
                        <td align="left" rowspan="1" colspan="1">10/10 (100%)</td>
                        <td align="left" rowspan="1" colspan="1">N/A</td>
                        <td align="left" rowspan="1" colspan="1">N/A</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Additional diagnosed medical conditions</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Gastrointestinal disease (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">0/9<xref rid="fsb222173-note-0003" ref-type="table-fn"><sup>a</sup></xref> (0%)</td>
                        <td align="left" rowspan="1" colspan="1">3/10 (30%)</td>
                        <td align="left" rowspan="1" colspan="1">.2105</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Skin conditions (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">1/9<xref rid="fsb222173-note-0003" ref-type="table-fn"><sup>a</sup></xref> (11.11%)</td>
                        <td align="left" rowspan="1" colspan="1">2/10 (20%)</td>
                        <td align="left" rowspan="1" colspan="1">&gt;.999</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Lifestyle factors</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Alcohol use (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">8/9<xref rid="fsb222173-note-0003" ref-type="table-fn"><sup>a</sup></xref> (88.89%)</td>
                        <td align="left" rowspan="1" colspan="1">5/10 (50%)</td>
                        <td align="left" rowspan="1" colspan="1">.1409</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diet including red meat (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">9/9<xref rid="fsb222173-note-0003" ref-type="table-fn"><sup>a</sup></xref> (100%)</td>
                        <td align="left" rowspan="1" colspan="1">10/10 (100%)</td>
                        <td align="left" rowspan="1" colspan="1">&gt;.999</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Tobacco use present (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">1/9<xref rid="fsb222173-note-0003" ref-type="table-fn"><sup>a</sup></xref> (11.11%)</td>
                        <td align="left" rowspan="1" colspan="1">1/10 (10%)</td>
                        <td align="left" rowspan="1" colspan="1">&gt;.999</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Tobacco use past (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">1/9<xref rid="fsb222173-note-0003" ref-type="table-fn"><sup>a</sup></xref> (11.11%)</td>
                        <td align="left" rowspan="1" colspan="1">10/10 (100%)</td>
                        <td align="left" rowspan="1" colspan="1">.0001</td>
                        <td align="left" rowspan="1" colspan="1">***</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Clinical measurements</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">Blood pressure</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td>
                        <td align="left" rowspan="1" colspan="1">75.4 ± 10.13</td>
                        <td align="left" rowspan="1" colspan="1">77.4 ± 11.63</td>
                        <td align="left" rowspan="1" colspan="1">.7910</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td>
                        <td align="left" rowspan="1" colspan="1">126.9 ± 19.30</td>
                        <td align="left" rowspan="1" colspan="1">151 ± 12.63</td>
                        <td align="left" rowspan="1" colspan="1">.0040</td>
                        <td align="left" rowspan="1" colspan="1">**</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Pulse (beats/min)</td>
                        <td align="left" rowspan="1" colspan="1">65.4 ± 7.56</td>
                        <td align="left" rowspan="1" colspan="1">70.4 ± 14.01</td>
                        <td align="left" rowspan="1" colspan="1">.2720</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">Inflammation</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">C‐reactive protein (mg/L)</td>
                        <td align="left" rowspan="1" colspan="1">1.13 ± 1.14</td>
                        <td align="left" rowspan="1" colspan="1">3.42 ± 3.05</td>
                        <td align="left" rowspan="1" colspan="1">.0445</td>
                        <td align="left" rowspan="1" colspan="1">*</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">White blood cell count (10⁹/L)</td>
                        <td align="left" rowspan="1" colspan="1">4.79 ± 0.97</td>
                        <td align="left" rowspan="1" colspan="1">7.06 ± 2.04</td>
                        <td align="left" rowspan="1" colspan="1">.0188</td>
                        <td align="left" rowspan="1" colspan="1">*</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">Liver function enzymes</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">AST (µkat/L)</td>
                        <td align="left" rowspan="1" colspan="1">0.4 ± 0.06</td>
                        <td align="left" rowspan="1" colspan="1">0.49 ± 0.25</td>
                        <td align="left" rowspan="1" colspan="1">.9090</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">ALT (µkat/L)</td>
                        <td align="left" rowspan="1" colspan="1">0.34 ± 0.11</td>
                        <td align="left" rowspan="1" colspan="1">0.43 ± 0.27</td>
                        <td align="left" rowspan="1" colspan="1">.8200</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">ALP (µkat/L)</td>
                        <td align="left" rowspan="1" colspan="1">1.18 ± 0.27</td>
                        <td align="left" rowspan="1" colspan="1">1.84 ± 0.92</td>
                        <td align="left" rowspan="1" colspan="1">.0615</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">GGT (µkat/L)</td>
                        <td align="left" rowspan="1" colspan="1">0.34 ± 0.22</td>
                        <td align="left" rowspan="1" colspan="1">1.29 ± 1.35</td>
                        <td align="left" rowspan="1" colspan="1">.0586</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">Metabolic analytes</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Fasting glucose, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">5.38 ± 0.44</td>
                        <td align="left" rowspan="1" colspan="1">6.09 ± 1.20</td>
                        <td align="left" rowspan="1" colspan="1">.2270</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">HbA1C (mmol/mol)</td>
                        <td align="left" rowspan="1" colspan="1">38 ± 2.31</td>
                        <td align="left" rowspan="1" colspan="1">40.7 ± 6.22</td>
                        <td align="left" rowspan="1" colspan="1">.4030</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Insulin (mIE/L)</td>
                        <td align="left" rowspan="1" colspan="1">4.59 ± 1.52</td>
                        <td align="left" rowspan="1" colspan="1">12.88 ± 8.20</td>
                        <td align="left" rowspan="1" colspan="1">.0017</td>
                        <td align="left" rowspan="1" colspan="1">**</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">HOMA %S (insulin sensitivity)</td>
                        <td align="left" rowspan="1" colspan="1">188.89 ± 43.99</td>
                        <td align="left" rowspan="1" colspan="1">100.54 ± 56.95</td>
                        <td align="left" rowspan="1" colspan="1">.0093</td>
                        <td align="left" rowspan="1" colspan="1">**</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">HOMA %B (pancreatic function)</td>
                        <td align="left" rowspan="1" colspan="1">54.84 ± 12.37</td>
                        <td align="left" rowspan="1" colspan="1">74.72 ± 19.46</td>
                        <td align="left" rowspan="1" colspan="1">.0673</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">HOMA‐IR (insulin resistance)</td>
                        <td align="left" rowspan="1" colspan="1">0.56 ± 0.16</td>
                        <td align="left" rowspan="1" colspan="1">1.36 ± 0.81</td>
                        <td align="left" rowspan="1" colspan="1">.0081</td>
                        <td align="left" rowspan="1" colspan="1">**</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">Blood lipids</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Cholesterol (mmol/L)</td>
                        <td align="left" rowspan="1" colspan="1">6.15 ± 0.74</td>
                        <td align="left" rowspan="1" colspan="1">3.52 ± 0.69</td>
                        <td align="left" rowspan="1" colspan="1">.0002</td>
                        <td align="left" rowspan="1" colspan="1">***</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">LDL cholesterol (mmol/L)</td>
                        <td align="left" rowspan="1" colspan="1">4.22 ± 0.85</td>
                        <td align="left" rowspan="1" colspan="1">1.87 ± 0.61</td>
                        <td align="left" rowspan="1" colspan="1">.0003</td>
                        <td align="left" rowspan="1" colspan="1">***</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">HDL cholesterol (mmol/L)</td>
                        <td align="left" rowspan="1" colspan="1">1.82 ± 0.51</td>
                        <td align="left" rowspan="1" colspan="1">1.33 ± 0.39</td>
                        <td align="left" rowspan="1" colspan="1">.0401</td>
                        <td align="left" rowspan="1" colspan="1">*</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Triglycerides (mmol/L)</td>
                        <td align="left" rowspan="1" colspan="1">1.01 ± 0.26</td>
                        <td align="left" rowspan="1" colspan="1">1.27 ± 0.59</td>
                        <td align="left" rowspan="1" colspan="1">.4950</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">Platelet number and coagulation</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Platelet count (10⁹/L)</td>
                        <td align="left" rowspan="1" colspan="1">270.5 ± 38.39</td>
                        <td align="left" rowspan="1" colspan="1">246.5 ± 73.71</td>
                        <td align="left" rowspan="1" colspan="1">.3070</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">APTT (sec)</td>
                        <td align="left" rowspan="1" colspan="1">26.1 ± 1.37</td>
                        <td align="left" rowspan="1" colspan="1">28.4 ± 3.53</td>
                        <td align="left" rowspan="1" colspan="1">.1030</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">PCC (INR)</td>
                        <td align="left" rowspan="1" colspan="1">1.02 ± 0.11</td>
                        <td align="left" rowspan="1" colspan="1">1.05 ± 0.10</td>
                        <td align="left" rowspan="1" colspan="1">.3830</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">Blood proteins</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Albumin (g/L)</td>
                        <td align="left" rowspan="1" colspan="1">39.4 ± 2.17</td>
                        <td align="left" rowspan="1" colspan="1">36.78 ± 0.97</td>
                        <td align="left" rowspan="1" colspan="1">.0034</td>
                        <td align="left" rowspan="1" colspan="1">**</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Medications</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Anti‐coagulant (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">0/10 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">3/10 (30%)</td>
                        <td align="left" rowspan="1" colspan="1">.2105</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Anti‐hypertensive (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">0/10 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">9/10 (90%)</td>
                        <td align="left" rowspan="1" colspan="1">.0001</td>
                        <td align="left" rowspan="1" colspan="1">***</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Anti‐inflammatory (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">0/10 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">3/10 (30%)</td>
                        <td align="left" rowspan="1" colspan="1">.2105</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">0/10 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">2/10 (20%)</td>
                        <td align="left" rowspan="1" colspan="1">.4737</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Immunosuppressive (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">0/10 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">0/10 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">&gt;.999</td>
                        <td align="left" rowspan="1" colspan="1">ns</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lipid lowering (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">0/10 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">8/10 (80%)</td>
                        <td align="left" rowspan="1" colspan="1">.0007</td>
                        <td align="left" rowspan="1" colspan="1">***</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Platelet inhibitor (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">0/10 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">10/10 (100%)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;.0001</td>
                        <td align="left" rowspan="1" colspan="1">****</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">3/10 (30%)</td>
                        <td align="left" rowspan="1" colspan="1">9/10 (90%)</td>
                        <td align="left" rowspan="1" colspan="1">.0198</td>
                        <td align="left" rowspan="1" colspan="1">*</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Specialized pro‐resolving mediator‐related medications</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Low‐dose aspirin (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">0/10 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">9/10 (90%)</td>
                        <td align="left" rowspan="1" colspan="1">.0001</td>
                        <td align="left" rowspan="1" colspan="1">***</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Statins (<italic toggle="yes">n</italic>, %)</td>
                        <td align="left" rowspan="1" colspan="1">0/10 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">9/10 (90%)</td>
                        <td align="left" rowspan="1" colspan="1">.0001</td>
                        <td align="left" rowspan="1" colspan="1">***</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="fsb222173-ntgp-0001">
                    <title>Note</title>
                    <fn id="fsb222173-note-0001">
                      <p>Data are presented as mean ± SD. <italic toggle="yes">p</italic>‐Values for continuous variables were calculated using Mann–Whitney <italic toggle="yes">U</italic>. <italic toggle="yes">p</italic>‐Values for categorical variables were calculated using Fisher's exact test.</p>
                    </fn>
                    <fn id="fsb222173-note-0002">
                      <p>Abbreviations: ALT, alanine transaminase; ALP, alkaline phosphatase; APTT, activated partial thromboplastin time; AST, aspartate transaminase; HOMA, homeostatic model assessment; GGT, gamma‐glutamyltransferase; PCC, prothrombin complex concentrate.</p>
                    </fn>
                    <fn id="fsb222173-note-0003">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>One participant declined to answer lifestyle questions and diagnosed medical conditions.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
              </sec>
              <sec id="fsb222173-sec-0004">
                <label>2.2</label>
                <title>Blood collection</title>
                <p>Venous blood samples were collected after an overnight fast in tubes spray‐coated with K<sub>2</sub>EDTA (Greiner Bio One, Kremsmünster, Upper Austria, Austria), citrate (Greiner Bio One), sodium‐heparin (Becton Dickinson and Company, Franklin Lakes, New Jersey, United States), or lithium‐heparin (Becton Dickinson and Company) as described.<xref rid="fsb222173-bib-0037" ref-type="bibr"><sup>37</sup></xref> Routine clinical tests were performed using lithium‐heparin blood (liver status, blood lipids, C‐reactive protein, insulin), citrate blood (coagulation status), and EDTA blood (HbA1c, pan‐leukocyte, and platelet counts), as detailed in Table <xref rid="fsb222173-tbl-0001" ref-type="table">1</xref>. For experimental procedures, sodium‐heparin blood was used for whole blood stimulation experiments, as described below, and EDTA blood was used for neutrophil transmigration experiments.</p>
              </sec>
              <sec id="fsb222173-sec-0005">
                <label>2.3</label>
                <title>Lipoxin treatment and inflammatory stimulation of whole blood samples</title>
                <p>Whole blood collected in sodium‐heparin tubes was stimulated with vehicle (0.16% ethanol), LXA<sub>4</sub> (500 nM, #437725, Calbiochem, San Diego, United States) or LXB<sub>4</sub> (500 nM, #90420, Cayman Chemical, Ann Arbor, Michigan, United States) for 10 min at room temperature, after which it was cooled for 10 min on ice before stimulation. Briefly, 100 μl whole blood was stimulated for 20 min at 37°C with either 0.4 μM chemotactic peptide N‐formyl‐Met‐Leu‐Phe (fMLP), 1.5 × 10<sup>7</sup> opsonized <italic toggle="yes">Escherichia coli</italic>, or 1 μM phorbol 12‐myristate 13‐acetate (PMA), all part of the PhagoBurst kit (#341058, Becton Dickinson and Company, Franklin Lakes, New Jersey, United States). Sodium chloride was added to the unstimulated samples as a vehicle treatment to ensure equal final volumes of all tests. Subsequently, neutrophil oxidative burst/ROS production and cellular receptor expression were quantified using flow cytometry as described below.</p>
              </sec>
              <sec id="fsb222173-sec-0006">
                <label>2.4</label>
                <title>Measuring neutrophil reactive oxygen species production</title>
                <p>Oxidative burst/ROS production was measured using the PhagoBurst assay, whereby ROS is quantified when the fluorogenic substrate, dihydrorhodamine 123 (DHR), is taken up by the cell and oxidized by ROS into the fluorescent rhodamine 123. Briefly, 20 μl of DHR was prepared as per the manufacturer's instructions (PhagoBurst, #341058, Becton Dickinson and Company, Franklin Lakes, New Jersey, United States) and added to the whole blood while resting on ice, immediately before the 37°C stimulation with inflammatory stimuli (described above). After stimulation, the tubes were placed on ice for 5 min to halt the ROS production, and cells were stained with CD16 (BV510, clone 3G8 #302048, BioLegend, San Diego, California, United States) in Brilliant Stain Buffer (Becton Dickinson and Company, Franklin Lakes, New Jersey, United States) in the dark for 10 min on ice and subsequently 20 min at room temperature. To lyse red blood cells, FACS lysing solution (#349202, Becton Dickinson and Company, Franklin Lakes, New Jersey, United States) was added and incubated for 15 min at room temperature. The stained blood samples were centrifuged (460<italic toggle="yes">g</italic>, 5 min, 4°C), and stained cells were washed in FACS buffer (phosphate‐buffered saline [PBS] with 2% fetal bovine serum) twice (460<italic toggle="yes">g</italic>, 5 min, 4°C) and analyzed immediately with a Beckman Coulter Gallios flow cytometer. A total of 25000 events in the granulocyte gate (forward scatter [FSC]<sup>high</sup> side scatter [SSC]<sup>high</sup>) were acquired. The data were analyzed with the FlowJo software (version 10.7, Tree Star, Ashland, Oregon, United States). Neutrophil gates were made based on SSC<sup>high</sup>CD16<sup>bright</sup> events and single‐cell gating before analysis of DHR positivity (Figure <xref rid="fsb222173-sup-0001" ref-type="supplementary-material">S1</xref>A,B).</p>
              </sec>
              <sec id="fsb222173-sec-0007">
                <label>2.5</label>
                <title>PhagoTest assay</title>
                <p>Samples from healthy controls were prepared as described in Section <xref rid="fsb222173-sec-0005" ref-type="sec">2.3</xref>. The phagocytosis rate of <italic toggle="yes">E. coli</italic> in neutrophils was measured as per manufacturer's instructions (PhagoTest, #341060, Becton Dickinson and Company, Franklin Lakes, New Jersey, United States), using 1.5 × 10<sup>7</sup> opsonized FITC‐labelled <italic toggle="yes">E. coli</italic> per sample. Neutrophil gates were made based on live leukocytes determined by DNA staining, followed by characteristic FSC<sup>high</sup>/SSC<sup>high</sup> neutrophils and single‐cell gating, before analysis of FITC positive neutrophils (Figure <xref rid="fsb222173-sup-0003" ref-type="supplementary-material">S3</xref>). A sample kept on ice was used as a gating control, as the cold prevents the cellular uptake of FITC‐<italic toggle="yes">E. coli</italic>.</p>
              </sec>
              <sec id="fsb222173-sec-0008">
                <label>2.6</label>
                <title>Measuring neutrophil receptor expression</title>
                <p>Neutrophil expression of SPM receptors and the CD11b integrin were quantified by flow cytometry. Blood was placed on ice for 5 min and stained in Brilliant Stain Buffer with CD11b‐FITC (high‐affinity conformation, clone CBRM1/5, #11‐0113‐41, eBioscience, San Diego, California, United States) and FPRL1/FPR2‐PE (aka FPR2/ALX, clone 304405, #FAB3479P, R&amp;D Systems Inc., Minneapolis, Minnesota, United States). To facilitate gating of neutrophils, the cells were also stained with CD45‐PerCP (Clone 2D1, #345809), CD16‐APC‐H7 (Clone 3G8, #560248), and CD14‐BV786, (Clone M5E2, #563699), which were obtained from Becton Dickinson and Company, Franklin Lakes, New Jersey, United States. Following the addition of antibodies, the samples were vortexed and incubated in the dark for 15 min at room temperature. To lyse the red blood cells, FACS lysing solution was added to the samples, which were then vortexed and incubated in the dark for 15 min at room temperature. The samples were centrifuged (320<italic toggle="yes">g</italic>, 5 min, room temperature), and stained cells were washed with PBS with human serum albumin twice (320<italic toggle="yes">g</italic>, 5 min, room temperature) before acquiring using BD FACSLyric flow cytometer. One hundred thousand events were acquired in the leukocyte gate using BD FACS Suite (version 1.4, Becton Dickinson and Company, Franklin Lakes, New Jersey, United States). The data were analyzed in Kaluza (version 2.1, Beckman Coulter, Brea, California, United States) and FlowJo software (version 10.7, Tree Star, Ashland, Oregon, United States), and gates were made as described in Figure <xref rid="fsb222173-sup-0001" ref-type="supplementary-material">S1</xref>C,D.</p>
              </sec>
              <sec id="fsb222173-sec-0009">
                <label>2.7</label>
                <title>Neutrophil lymphatic transmigration assay</title>
                <sec id="fsb222173-sec-0010">
                  <label>2.7.1</label>
                  <title>Cell culture</title>
                  <p>Human dermal lymphatic microvascular endothelial cells (LECs) were purchased from Lonza (#CC‐2810, Basel city, Basel, Switzerland). LECs were cultured in the culture media recommended by the company, that is, EGM‐2MV media (#CC‐3202, Lonza, Basel city, Basel, Switzerland) containing the included SingleQuots Bullet kit with fetal bovine serum, hydrocortisone, hFGF‐B, VEGF, R3‐IGF‐1, ascorbic acid, hEGF, and GA‐100 in 75 cm<sup>2</sup> culture flasks coated with 0.1% gelatin in a horizontal position. Cells were cultured in a 5% CO<sub>2</sub> atmosphere at 37°C. Once cells reached 70% to 85% confluency, they were released with trypsin‐EDTA (4–7 min) and split at a concentration of 5000 cells/cm<sup>2</sup> into new flasks. LECs were used for transmigration experiments between passages 5–11.</p>
                </sec>
                <sec id="fsb222173-sec-0011">
                  <label>2.7.2</label>
                  <title>Seeding lymphatic endothelial cells onto transwells</title>
                  <p>LECs were seeded on a 24‐well transwell plate insert with 5 μm pore size (#3421, Corning International, New York, New York, United States), as previously described.<xref rid="fsb222173-bib-0038" ref-type="bibr"><sup>38</sup></xref> Briefly, transwells were flipped upside‐down into a 12‐well plate, where four empty wells contained PBS for a humidified atmosphere. The transwells were coated with 100 μl of 0.1% gelatin for a minimum of 30 min at 37°C. The remaining gelatin liquid was aspirated off, and LECs (100,000 cells in 100 μl complete EGM‐2MV media) were seeded on the upside‐down flipped transwells. The plate lid of the 12‐well plate was gently placed on top of the plate, thus allowing the media to touch the lid, whereby the liquid surface tension with the humidified atmosphere ensured that the media did not evaporate. The media was refreshed after 48 hours. On the third day post‐seeding, the transwells were washed with migration media, defined as Iscove's Modified Dulbecco's Medium (#12440‐046, Thermo Fisher Scientific Life Sciences, Waltham, Massachusetts, United States), insulin‐transferrin 1:100 (#41400‐045, Thermo Fisher Scientific Life Sciences) and 1% bovine serum albumin (#700‐107P, GeminiBio, West Sacramento, California, United States). The transwells were immediately flipped (180°) into 600 μl of migration media, containing either vehicle or 5 ng/ml interleukin (IL)‐8 (R&amp;D Systems Inc., Minneapolis, Minnesota, United States).</p>
                </sec>
                <sec id="fsb222173-sec-0012">
                  <label>2.7.3</label>
                  <title>Neutrophil isolation and staining</title>
                  <p>Human neutrophils were isolated using negative bead isolation with the EasySep Direct Human Neutrophil Isolation kit (#19666, StemCell, Vancouver, British Columbia, Canada) with minor modifications. In order to obtain a purer population of neutrophils (98%–99% of isolated cells were characterized as CD45<sup>+</sup>CD16<sup>+</sup>CD66b<sup>+</sup> neutrophils), we added an additional amount (50% of recommended concentration) of the EasySep Pan‐Granulocyte Isolation Cocktail (#19659C, StemCell, Vancouver, British Columbia, Canada) to the original volume of Neutrophil Isolation Cocktail. Isolated neutrophils were then centrifuged (400<italic toggle="yes">g</italic>, 7 min, 4°C) and washed in PBS without calcium or magnesium (400<italic toggle="yes">g</italic>, 7 min, 4°C) before being resuspended in migration media (defined above) containing 5 µM CellTracker Green (Thermo Fisher Scientific Life Sciences, Waltham, MA, United States). Cells were stained on a shaker at 300 rpm, 15 min at 37°C. Following a wash (400<italic toggle="yes">g</italic>, 7 min, 4°C), cells were resuspended in migration media and recovered for 45–60 min at 37°C in a 5% CO<sub>2</sub> atmosphere.</p>
                </sec>
                <sec id="fsb222173-sec-0013">
                  <label>2.7.4</label>
                  <title>Lipoxin treatment of isolated neutrophils</title>
                  <p>As opposed to whole blood, where a higher lipoxin concentration is needed due to the presence of serum albumin,<xref rid="fsb222173-bib-0010" ref-type="bibr"><sup>10</sup></xref> isolated neutrophils were treated with vehicle (0.01% ethanol), LXA<sub>4</sub> (1 nM), or LXB<sub>4</sub> (1 nM) for 15 min at 37°C. Subsequently, 5 × 10<sup>5</sup> neutrophils in 100 µl of migration media were added to the upper chamber of the transwell, which had just been flipped into migration media containing vehicle or IL‐8 (5 ng/ml). Additional vehicle (0.01% ethanol), LXA<sub>4</sub> (1 nM), or LXB<sub>4</sub> (1 nM) was added to the lower chamber of the transwells.</p>
                </sec>
                <sec id="fsb222173-sec-0014">
                  <label>2.7.5</label>
                  <title>Neutrophil transmigration assay</title>
                  <p>After the neutrophils migrated for 3 hours toward either vehicle or the chemoattractant, IL‐8, cells were collected from the lower chamber of the transwell. The cells were counted using an Accuri C6 flow cytometer (Becton Dickinson and Company, Franklin Lakes, New Jersey, United States) by acquiring 50 μl of cell suspension and back calculating the cell concentration based on expected volume (600 μl) in the lower chamber. CellTracker Green labelled neutrophils were easily distinguishable from contaminating LECs, which may have loosened from the transwell. The percentage of transmigrated neutrophils was calculated based on the lower chamber's cell count divided by the total sum of cells added multiplied by 100.</p>
                </sec>
              </sec>
              <sec id="fsb222173-sec-0015">
                <label>2.8</label>
                <title>Lipid mediator profiling</title>
                <p>Lipid mediators in human serum samples were extracted, identified, and quantified as described.<xref rid="fsb222173-bib-0039" ref-type="bibr"><sup>39</sup></xref> In brief, after the addition of four volumes of ice‐cold methanol containing d<sub>5</sub>‐RvD2, d<sub>5</sub>‐RvE1, d<sub>5</sub>‐RvD3, d<sub>5</sub>‐17R‐RvD1, d<sub>5</sub>‐LXA<sub>4</sub>, d<sub>5</sub>‐MaR2, d<sub>5</sub>‐MaR1, d<sub>4</sub>‐PGE<sub>2</sub>, d<sub>5</sub>‐LTC<sub>4</sub>, d<sub>5</sub>‐LTD<sub>4</sub>, d<sub>5</sub>‐LTE<sub>4</sub>, and d<sub>5</sub>‐LTB<sub>4</sub>, samples were placed at −20°C for 45 min to allow for protein precipitation. The lipid mediators were extracted using an ExtraHera liquid handling system (Biotage, Uppsala, Sweden) and solid phase extraction techniques with Isolute C18 500mg columns (Biotage). Methyl formate and methanol fractions were collected, brought to dryness and resuspended in phase (methanol/water, 1:1, vol/vol) for injection on a Shimadzu LC‐20AD HPLC and a Shimadzu SIL‐20AC autoinjector, paired with a QTrap 6500+ or QTrap 5500 (Sciex, Framingham, Massachusetts, United States). For the identification and quantitation of mediators eluted in methyl formate fractions the QTRAP was operated in negative ion mode using a multiple reaction monitoring method coupled with an information dependent acquisition to an Enhanced Product Ion experiment. An Agilent Poroshell 120 EC‐C18 column (100 mm × 4.6 mm × 2.7 μm) was kept at 50°C and mediators eluted using a mobile phase consisting of methanol/water/acetic acid of 20:80:0.01 (vol/vol/vol) that was ramped to 50:50:0.01 (vol/vol/vol) over 0.5 min and then to 80:20:0.01 (vol/vol/vol) from 2 min to 11 min, maintained till 14.5 min and then rapidly ramped to 98:2:0.01 (vol/vol/vol) for the next 0.1 min. This was subsequently maintained at 98:2:0.01 (vol/vol/vol) for 5.4 min, and the flow rate was maintained at 0.5 ml/min. In the analysis of mediators eluted in the methanol fraction, the QTrap 6500+ was operated in positive ion mode using a multiple reaction monitoring method. An Agilent Poroshell 120 EC‐C18 column (100 mm × 4.6 mm × 2.7 μm) was kept at 50°C and mediators eluted using a mobile phase consisting of methanol/water/acetic acid 55:45:0.5 (vol/vol/vol) over 5 min, that was ramped to 80:20:0.5 (vol/vol/vol) for 2 min, maintained at 80:20:0.5 (vol/vol/vol) for the successive 3 min and ramped to 98:2:0.5 (vol/vol/vol) over 3 min. This condition was maintained for 3 min. Each lipid mediator was identified using established criteria,<xref rid="fsb222173-bib-0039" ref-type="bibr"><sup>39</sup></xref>, <xref rid="fsb222173-bib-0040" ref-type="bibr"><sup>40</sup></xref> including the following: (1) matching retention time to synthetic or authentic standards, (2) ≥8 data points, and (3) matching of MS/MS spectrum to that of reference standard in representative samples. For quantitation the following criteria were used: (1) matching retention time to synthetic or authentic standards, (2) ≥8 data points, (3) signal to noise ratio ≥4. Calibration curves were obtained for each mediator using synthetic compound mixtures at 0.78, 1.56, 3.12, 6.25, 12.5, 25, 50, 100, and 200 pg that gave linear calibration curves with <italic toggle="yes">R</italic>
<sup>2</sup> values of 0.98–0.99.</p>
              </sec>
              <sec id="fsb222173-sec-0016">
                <label>2.9</label>
                <title>Statistical analyses</title>
                <p>Data were analyzed using GraphPad (version 7.04, San Diego, California, United States). Assuming non‐Gaussian distribution of the human samples, statistical significance (<italic toggle="yes">p</italic> &lt; .05) for continuous variables was determined using Mann–Whitney <italic toggle="yes">U</italic> test when comparing two groups, and Kruskal‐Wallis test with Dunn's post hoc comparisons when comparing over two groups. Statistical significance (<italic toggle="yes">p</italic> &lt; .05) for categorical variables was calculated using Fisher's exact test. All statistical significance for lipoxin treatments were calculated based on the log<sub>2</sub> of the fold change relative to vehicle treatment. Data are presented as mean ± standard error of the mean (SEM) or mean ± standard deviation (SD), as stated in respective figure or table legend.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="fsb222173-sec-0017">
              <label>3</label>
              <title>RESULTS</title>
              <sec id="fsb222173-sec-0018">
                <label>3.1</label>
                <title>Cohort characteristics</title>
                <p>We compared the clinical status of the patients diagnosed with atherosclerosis and the healthy controls. Briefly, their clinical characteristics, anthropometrics, cardiovascular risk factors, medical history, and drug regimen were recorded (Table <xref rid="fsb222173-tbl-0001" ref-type="table">1</xref>). The patients with atherosclerosis were older than the control group (59.6 ± 4.88 vs. 75.1 ± 4.84 years: <italic toggle="yes">p</italic> = .0002). However, as the healthy controls were over 50 years old, the potential impact of “inflammaging” should be minimized.<xref rid="fsb222173-bib-0036" ref-type="bibr"><sup>36</sup></xref> One patient with atherosclerosis was diagnosed with type 2 diabetes mellitus. Both the patient and control groups had well‐controlled blood sugar, as evidenced by normal levels of whole blood glycosylated hemoglobin (HbA1c), which provides the average blood sugar levels for the 6–12 weeks prior to the blood draw. There was no difference in body mass index (BMI) between the groups, although the patients with atherosclerosis had signs of elevated central adiposity (i.e., higher sagittal height, waist circumference, and waist‐to‐height ratio), compared with the control group. We unexpectedly found that compared with healthy controls, the atherosclerosis cohort had lower cholesterol (6.15 ± 0.74 vs. 3.52 ± 0.69 mmol/L, respectively: <italic toggle="yes">p</italic> = .0002) and low‐density lipoprotein (LDL) cholesterol (4.22 ± 0.85 vs. 1.87 ± 0.61, respectively: <italic toggle="yes">p</italic> = .0003). This is likely due to lipid‐lowering drugs (statins) that were used by 90% of the patients (Table <xref rid="fsb222173-tbl-0001" ref-type="table">1</xref>). Patients with atherosclerosis displayed elevated markers of systemic inflammation compared with controls, that is, plasma levels of C‐reactive protein (1.13 ± 1.14 vs. 3.42 ± 3.05 mg/ml, respectively: <italic toggle="yes">p</italic> = .0445) and circulating leukocytes (4.79 ± 0.97 vs. 7.06 ± 2.04 × 10<sup>9</sup> cells/L, respectively: <italic toggle="yes">p</italic> = .0188). However, there were no differences between the groups regarding liver function tests, that is, alanine transaminase, aspartate transaminase, alkaline phosphatase, or gamma‐glutamyltransferase levels. All patients with atherosclerosis had a history of smoking, whereas only one healthy control was a former smoker (<italic toggle="yes">p</italic> = .0001). It may be important to note that the patients with atherosclerosis were taking medications that may alter endogenous SPM production, such as low‐dose aspirin and statins,<xref rid="fsb222173-bib-0020" ref-type="bibr"><sup>20</sup></xref>, <xref rid="fsb222173-bib-0041" ref-type="bibr"><sup>41</sup></xref>, <xref rid="fsb222173-bib-0042" ref-type="bibr"><sup>42</sup></xref>, <xref rid="fsb222173-bib-0043" ref-type="bibr"><sup>43</sup></xref> which is, therefore, highlighted in Table <xref rid="fsb222173-tbl-0001" ref-type="table">1</xref>.</p>
              </sec>
              <sec id="fsb222173-sec-0019">
                <label>3.2</label>
                <title>Neutrophils reactive oxygen species production is elevated in patients with atherosclerosis compared with healthy controls and is inversely modulated by lipoxins</title>
                <p>The neutrophil oxidative burst process is critical to the host's defense against certain pathogens.<xref rid="fsb222173-bib-0044" ref-type="bibr"><sup>44</sup></xref> However, exacerbated ROS production amplifies the pro‐atherogenic inflammatory environment.<xref rid="fsb222173-bib-0035" ref-type="bibr"><sup>35</sup></xref> The PhagoBurst assay was used to determine differences in neutrophil ROS production between patients with atherosclerosis and healthy controls (Figure <xref rid="fsb222173-fig-0001" ref-type="fig">1A</xref>). We analyzed both the percentages of cells having produced intracellular ROS (i.e., DHR+ cells) and the mean fluorescence intensity (MFI) of DHR in the neutrophil population. ROS production was measured both at baseline (unstimulated cells) and in response to inflammatory stimuli: chemotactic peptide (fMLP) and whole bacteria (opsonized <italic toggle="yes">E. coli</italic>). Maximal ROS production was defined as the cellular response to PMA stimulation.</p>
                <fig position="float" fig-type="FIGURE" id="fsb222173-fig-0001">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>Lipoxins modulate oxidative burst in human neutrophils from patients with atherosclerosis and healthy controls. Whole blood from healthy controls (<italic toggle="yes">n</italic> = 7) or patients with atherosclerosis (<italic toggle="yes">n</italic> = 6) was exposed to an inflammatory stimulus, either in the absence or presence of lipoxin A<sub>4</sub> (LXA<sub>4</sub>: 500 nM) or lipoxin B<sub>4</sub> (LXB<sub>4</sub>: 500 nM). Neutrophil reactive oxygen species (ROS) production was measured by flow cytometry and reported as DHR positivity. The percentage ROS‐positive neutrophils (DHR+) was determined in relation to a 1% baseline, which was set using an unstimulated control sample and kept constant throughout the analysis. (A) Neutrophil ROS production was measured as % positive cells (left panel) and cellular mean fluorescence intensity (MFI) (right panel), in controls (white bars) and patients (gray bars). The cells were untreated (Unstim.) or stimulated with chemotactic peptide N‐formyl‐Met‐Leu‐Phe (fMLP, 0.4 μM) opsonized <italic toggle="yes">Escherichia coli</italic> (1.5 × 10<sup>7</sup>), or phorbol 12‐myristate 13‐acetate (PMA, 1 μM). Representative histograms of the MFI DHR‐signal in respective conditions are shown for controls (dashed line) and patients (solid line). (B) LXA<sub>4</sub> (blue bars) and LXB<sub>4</sub> (green bars)‐induced changes to ROS production was calculated as the log<sub>2</sub> fold change relative to respective vehicle‐treated condition. The cells were stimulated as indicated. The bar graphs show ROS levels as % positive cells (left panel) and cellular mean fluorescence intensity (MFI) (right panel). Representative histograms of the MFI DHR‐signal in respective conditions are shown for vehicle (black line), LXA<sub>4</sub> (blue line), and LXB<sub>4</sub> (green line). Assuming non‐Gaussian distribution of the human samples, statistical analysis was determined using Mann–Whitney <italic toggle="yes">U</italic> test when comparing two groups, and Kruskal–Wallis test with Dunn's post hoc comparisons when comparing more than two groups. Data are presented as mean ± standard error of the mean (SEM). Statistical significance is indicated as *<italic toggle="yes">p</italic> &lt; .05, **<italic toggle="yes">p</italic> &lt; .01, ***<italic toggle="yes">p</italic> &lt; .001, ****<italic toggle="yes">p</italic> &lt; .0001</p>
                  </caption>
                  <graphic xlink:href="FSB2-36-0-g004" position="anchor" id="jats-graphic-1"/>
                </fig>
                <p>At baseline, the percentages of DHR+ neutrophils were similar in control and patient cohorts. However, neutrophils from patients with atherosclerosis produced more ROS per cell (i.e., elevated MFI values) than healthy controls (<italic toggle="yes">p</italic> = .0221). In response to fMLP, the percentage of DHR+ neutrophils was approximately doubled in patients with atherosclerosis compared with controls (<italic toggle="yes">p</italic> = .001). In addition, ROS production per cell after fMLP stimulation was also higher in neutrophils from patients (<italic toggle="yes">p</italic> = .005). In response to <italic toggle="yes">E. coli</italic> stimulation, a significantly higher percentage of neutrophils from atherosclerosis patients produced ROS compared with the healthy controls (<italic toggle="yes">p</italic> = .001), although the ROS production per cell did not differ between groups. PMA stimulation represents the maximum ROS production, and it did not differ between patients and controls.</p>
                <p>To assess the effects of lipoxins on ROS production, whole blood was treated with vehicle (0.16% ethanol) or lipoxins (500 nM), prior to exposure to inflammatory stimuli (Figure <xref rid="fsb222173-fig-0001" ref-type="fig">1B</xref>). To highlight drug‐mediated effects, the fluorescence scale on the x‐axes of the representative histograms were adjusted for respective condition, and raw data may be found in Figure <xref rid="fsb222173-sup-0002" ref-type="supplementary-material">S2</xref>. The lipoxins manipulated neutrophil ROS production differently in the two cohorts. In healthy controls, LXB<sub>4</sub> amplified fMLP‐ and <italic toggle="yes">E. coli–</italic>induced ROS production, both regarding percentage of DHR+ neutrophils (<italic toggle="yes">p</italic> = .002, <italic toggle="yes">p</italic> &lt; .001, respectively) and the MFI (<italic toggle="yes">p</italic> = .035, <italic toggle="yes">p</italic> ≤ .001, respectively). In addition, in healthy individuals, LXA<sub>4</sub> increased <italic toggle="yes">E. coli</italic>–induced ROS production based on MFI (<italic toggle="yes">p</italic> = .0316). The lipoxin‐mediated increase in <italic toggle="yes">E. coli</italic>–induced ROS in the healthy controls was not related to an increased phagocytosis rate (Figure <xref rid="fsb222173-sup-0003" ref-type="supplementary-material">S3</xref>). In contrast, the lipoxins reduced the upregulated ROS production observed in the patient cohort. Specifically, both LXA<sub>4</sub> and LXB<sub>4</sub> treatment reduced the fMLP‐induced increase in ROS production, both with respect to percentage of DHR+ neutrophils (<italic toggle="yes">p</italic> = .047, <italic toggle="yes">p</italic> = .047, respectively), and the MFI (<italic toggle="yes">p</italic> = .013, <italic toggle="yes">p</italic> = .013, respectively).</p>
              </sec>
              <sec id="fsb222173-sec-0020">
                <label>3.3</label>
                <title>Expression of neutrophil specialized pro‐resolving mediator receptors in atherosclerosis patients versus healthy controls</title>
                <p>To determine the individual's capacity to induce the resolution of inflammation, we quantified the expression of the LXA<sub>4</sub> receptor, FPR2/ALX, on neutrophils from healthy controls and patients with atherosclerosis (Figure <xref rid="fsb222173-fig-0002" ref-type="fig">2A</xref>, Figure <xref rid="fsb222173-sup-0001" ref-type="supplementary-material">S1</xref>). Patients and healthy controls expressed similar FPR2/ALX receptor levels at baseline. In contrast, fMLP stimulation caused a significant decrease in the percentage of cells expressing FPR2/ALX in the patient cohort (<italic toggle="yes">p</italic> = .032), and a similar decreasing trend was observed in the healthy controls (<italic toggle="yes">p</italic> = .056). No significant difference in the MFI of FPR2/ALX was observed in either group in response to fMLP stimulation (<italic toggle="yes">p</italic> &gt; .999). We further investigated if lipoxin treatment could alter the SPM receptor expression. Thus, whole blood from patients and healthy controls was incubated with vehicle (0.16% ethanol) or lipoxins (500 nM) for 15 min prior to fMLP stimulation. Under these conditions, we found no difference in FRP2/ALX receptor expression in response to lipoxins in either patients or controls (Figure <xref rid="fsb222173-fig-0002" ref-type="fig">2B</xref>). As an additional measurement of endogenous resolution, we quantified the levels of pro‐resolving lipids in serum of healthy controls and patients (Table <xref rid="fsb222173-tbl-0002" ref-type="table">2</xref>). Factors that drive the separation between the cohorts were identified by a supervised partial least squares‐discriminant analysis (PLS‐DA) (Figure <xref rid="fsb222173-fig-0003" ref-type="fig">3A</xref>). To identify those lipid mediators that drive the group separation, we calculated the variable importance in projection (VIP) score. This analysis identified 10 mediators with VIP scores &gt;1, of which Maresin conjugates in tissue regeneration 3 (MCTR3) and 15‐epi LXA<sub>4</sub> concentrations were observed to display the highest differences between the two groups (Figure <xref rid="fsb222173-fig-0003" ref-type="fig">3B</xref>). Differences in the concentrations of these mediators were further corroborated following additional statistical evaluation. Of note, this analysis also demonstrated that 17R‐PD1, the aspirin triggered epimer of PD1, was also upregulated in patients with cardiovascular disease, likely reflecting aspirin intake in these patients.</p>
                <fig position="float" fig-type="FIGURE" id="fsb222173-fig-0002">
                  <label>FIGURE 2</label>
                  <caption>
                    <p>Lipoxin A<sub>4</sub> receptor, FPR2/ALX, expression on neutrophils from patients with atherosclerosis versus healthy controls. Whole blood from healthy controls (<italic toggle="yes">n</italic> = 5) or patients with atherosclerosis (<italic toggle="yes">n</italic> = 5) was exposed to inflammatory stimulus, either in the absence or presence of lipoxin A<sub>4</sub> (LXA<sub>4</sub>: 500 nM) or lipoxin B<sub>4</sub> (LXB<sub>4</sub>: 500 nM). The neutrophil surface expression of FPR2/ALX was measured by flow cytometry. (A) Neutrophil FPR2/ALX expressions were measured as % positive cells (left panel) and cellular mean fluorescence intensity (MFI) (right panel). The expression was measured in controls (white bars) and patients (gray bars). The cells were untreated (Unstim.) or stimulated with chemotactic peptide N‐formyl‐Met‐Leu‐Phe (fMLP, 0.4 μM). Representative histograms for the MFI of respective receptor expression and indicated conditions are shown for controls (dashed line) and patients (solid line), where the gates were determined using a negative population (gray shaded peaks). (B) LXA<sub>4</sub> (blue bars) and LXB<sub>4</sub> (green bars)‐induced changes to FPR2/ALX expression was calculated as the log<sub>2</sub> fold change relative to respective vehicle‐treated condition. The samples were stimulated as indicated. The bar graphs show levels as % marker positive cells (left panel) and MFI of indicated markers (right panel). Representative MFI histograms for each receptor expression under respective treatment conditions are shown for vehicle (black line), LXA<sub>4</sub> (blue line) and LXB<sub>4</sub> (green line), where the gates were determined using a negative population (gray shaded peaks). Assuming non‐Gaussian distribution of the human samples, statistical analysis was determined using Mann–Whitney <italic toggle="yes">U</italic> test when comparing two groups, and Kruskal–Wallis test with Dunn's post hoc comparisons when comparing more than two groups. Data are presented as mean ± standard error of the mean (SEM). Statistical significance is indicated as *<italic toggle="yes">p</italic> &lt; .05, **<italic toggle="yes">p</italic> &lt; .01, ***<italic toggle="yes">p</italic> &lt; .001</p>
                  </caption>
                  <graphic xlink:href="FSB2-36-0-g003" position="anchor" id="jats-graphic-3"/>
                </fig>
                <table-wrap position="float" id="fsb222173-tbl-0002" content-type="TABLE">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Serum lipid mediator profiles in controls and patient cohorts</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="left" valign="top" rowspan="1" colspan="1">Q1</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Q3</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Patients with atherosclerosis (pg/ml)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Controls (pg/ml)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic>‐Value</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Significance</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="7" rowspan="1">DHA bioactive metabolome</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RvD1</td>
                        <td align="left" rowspan="1" colspan="1">375</td>
                        <td align="left" rowspan="1" colspan="1">215</td>
                        <td align="left" rowspan="1" colspan="1">0.08 ± 0.15</td>
                        <td align="left" rowspan="1" colspan="1">0.05 ± 0.04</td>
                        <td align="left" rowspan="1" colspan="1">.0371</td>
                        <td align="left" rowspan="1" colspan="1">*</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">17R‐RvD1</td>
                        <td align="left" rowspan="1" colspan="1">375</td>
                        <td align="left" rowspan="1" colspan="1">215</td>
                        <td align="left" rowspan="1" colspan="1">0.01 ± 0.03</td>
                        <td align="left" rowspan="1" colspan="1">0.09 ± 0.08</td>
                        <td align="left" rowspan="1" colspan="1">.1662</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RvD2</td>
                        <td align="left" rowspan="1" colspan="1">375</td>
                        <td align="left" rowspan="1" colspan="1">215</td>
                        <td align="left" rowspan="1" colspan="1">0.23 ± 0.75</td>
                        <td align="left" rowspan="1" colspan="1">0.19 ± 0.21</td>
                        <td align="left" rowspan="1" colspan="1">.2053</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RvD3</td>
                        <td align="left" rowspan="1" colspan="1">375</td>
                        <td align="left" rowspan="1" colspan="1">147</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">17R‐RvD3</td>
                        <td align="left" rowspan="1" colspan="1">375</td>
                        <td align="left" rowspan="1" colspan="1">137</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RvD4</td>
                        <td align="left" rowspan="1" colspan="1">375</td>
                        <td align="left" rowspan="1" colspan="1">225</td>
                        <td align="left" rowspan="1" colspan="1">0.23 ± 0.86</td>
                        <td align="left" rowspan="1" colspan="1">0.65 ± 0.35</td>
                        <td align="left" rowspan="1" colspan="1">.3936</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RvD5</td>
                        <td align="left" rowspan="1" colspan="1">359</td>
                        <td align="left" rowspan="1" colspan="1">141</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RvD6</td>
                        <td align="left" rowspan="1" colspan="1">359</td>
                        <td align="left" rowspan="1" colspan="1">101</td>
                        <td align="left" rowspan="1" colspan="1">0.13 ± 0.39</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">PD1</td>
                        <td align="left" rowspan="1" colspan="1">359</td>
                        <td align="left" rowspan="1" colspan="1">153</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">10S,17S‐diHDHA</td>
                        <td align="left" rowspan="1" colspan="1">359</td>
                        <td align="left" rowspan="1" colspan="1">153</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">22‐OH‐PD1</td>
                        <td align="left" rowspan="1" colspan="1">359</td>
                        <td align="left" rowspan="1" colspan="1">153</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">17R‐PD1</td>
                        <td align="left" rowspan="1" colspan="1">359</td>
                        <td align="left" rowspan="1" colspan="1">153</td>
                        <td align="left" rowspan="1" colspan="1">0.09 ± 0.11</td>
                        <td align="left" rowspan="1" colspan="1">0.07 ± 0.06</td>
                        <td align="left" rowspan="1" colspan="1">.0491</td>
                        <td align="left" rowspan="1" colspan="1">*</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">PCTR1</td>
                        <td align="left" rowspan="1" colspan="1">650</td>
                        <td align="left" rowspan="1" colspan="1">231</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">0.34 ± 0.38</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">PCTR2</td>
                        <td align="left" rowspan="1" colspan="1">521</td>
                        <td align="left" rowspan="1" colspan="1">231</td>
                        <td align="left" rowspan="1" colspan="1">0.19 ± 0.25</td>
                        <td align="left" rowspan="1" colspan="1">0.30 ± 0.11</td>
                        <td align="left" rowspan="1" colspan="1">.2133</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">PCTR3</td>
                        <td align="left" rowspan="1" colspan="1">464</td>
                        <td align="left" rowspan="1" colspan="1">231</td>
                        <td align="left" rowspan="1" colspan="1">0.52 ± 2.22</td>
                        <td align="left" rowspan="1" colspan="1">0.39 ± 0.27</td>
                        <td align="left" rowspan="1" colspan="1">.2240</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">MCTR1</td>
                        <td align="left" rowspan="1" colspan="1">650</td>
                        <td align="left" rowspan="1" colspan="1">191</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">1.39 ± 1.29</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">MCTR2</td>
                        <td align="left" rowspan="1" colspan="1">521</td>
                        <td align="left" rowspan="1" colspan="1">191</td>
                        <td align="left" rowspan="1" colspan="1">0.03 ± 0.09</td>
                        <td align="left" rowspan="1" colspan="1">0.11 ± 0.07</td>
                        <td align="left" rowspan="1" colspan="1">.2858</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">MCTR3</td>
                        <td align="left" rowspan="1" colspan="1">464</td>
                        <td align="left" rowspan="1" colspan="1">191</td>
                        <td align="left" rowspan="1" colspan="1">0.15 ± 0.54</td>
                        <td align="left" rowspan="1" colspan="1">1.75 ± 0.16</td>
                        <td align="left" rowspan="1" colspan="1">.0003</td>
                        <td align="left" rowspan="1" colspan="1">***</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">MaR1</td>
                        <td align="left" rowspan="1" colspan="1">359</td>
                        <td align="left" rowspan="1" colspan="1">221</td>
                        <td align="left" rowspan="1" colspan="1">0.18 ± 0.64</td>
                        <td align="left" rowspan="1" colspan="1">1.08 ± 0.87</td>
                        <td align="left" rowspan="1" colspan="1">.2276</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">7S,14S‐diHDHA</td>
                        <td align="left" rowspan="1" colspan="1">359</td>
                        <td align="left" rowspan="1" colspan="1">221</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">MaR2</td>
                        <td align="left" rowspan="1" colspan="1">359</td>
                        <td align="left" rowspan="1" colspan="1">221</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">4S,14S‐diHDHA</td>
                        <td align="left" rowspan="1" colspan="1">359</td>
                        <td align="left" rowspan="1" colspan="1">101</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="7" rowspan="1">
                          <bold>n−3 DPA bioactive metabolome</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RvT1</td>
                        <td align="left" rowspan="1" colspan="1">377</td>
                        <td align="left" rowspan="1" colspan="1">193</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RvT2</td>
                        <td align="left" rowspan="1" colspan="1">377</td>
                        <td align="left" rowspan="1" colspan="1">197</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RvT3</td>
                        <td align="left" rowspan="1" colspan="1">377</td>
                        <td align="left" rowspan="1" colspan="1">197</td>
                        <td align="left" rowspan="1" colspan="1">0.02 ± 0.05</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RvT4</td>
                        <td align="left" rowspan="1" colspan="1">361</td>
                        <td align="left" rowspan="1" colspan="1">193</td>
                        <td align="left" rowspan="1" colspan="1">0.12 ± 0.34</td>
                        <td align="left" rowspan="1" colspan="1">0.17 ± 0.09</td>
                        <td align="left" rowspan="1" colspan="1">.2844</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RvD1<sub>n−3 DPA</sub>
</td>
                        <td align="left" rowspan="1" colspan="1">377</td>
                        <td align="left" rowspan="1" colspan="1">215</td>
                        <td align="left" rowspan="1" colspan="1">0.05 ± 0.10</td>
                        <td align="left" rowspan="1" colspan="1">0.06 ± 0.03</td>
                        <td align="left" rowspan="1" colspan="1">.1697</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RvD2<sub>n−3 DPA</sub>
</td>
                        <td align="left" rowspan="1" colspan="1">377</td>
                        <td align="left" rowspan="1" colspan="1">261</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RvD5<sub>n−3 DPA</sub>
</td>
                        <td align="left" rowspan="1" colspan="1">361</td>
                        <td align="left" rowspan="1" colspan="1">143</td>
                        <td align="left" rowspan="1" colspan="1">0.03 ± 0.11</td>
                        <td align="left" rowspan="1" colspan="1">0.04 ± 0.03</td>
                        <td align="left" rowspan="1" colspan="1">.3143</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">PD1<sub>n−3 DPA</sub>
</td>
                        <td align="left" rowspan="1" colspan="1">361</td>
                        <td align="left" rowspan="1" colspan="1">183</td>
                        <td align="left" rowspan="1" colspan="1">0.03 ± 0.14</td>
                        <td align="left" rowspan="1" colspan="1">0.51 ± 0.56</td>
                        <td align="left" rowspan="1" colspan="1">.2173</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">PD2<sub>n−3 DPA</sub>
</td>
                        <td align="left" rowspan="1" colspan="1">361</td>
                        <td align="left" rowspan="1" colspan="1">233</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">10S, 17S‐diHDPA</td>
                        <td align="left" rowspan="1" colspan="1">361</td>
                        <td align="left" rowspan="1" colspan="1">183</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">MaR1<sub>n−3 DPA</sub>
</td>
                        <td align="left" rowspan="1" colspan="1">361</td>
                        <td align="left" rowspan="1" colspan="1">223</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">MaR2<sub>n−3 DPA</sub>
</td>
                        <td align="left" rowspan="1" colspan="1">361</td>
                        <td align="left" rowspan="1" colspan="1">193</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">7S,14S‐diHDPA</td>
                        <td align="left" rowspan="1" colspan="1">361</td>
                        <td align="left" rowspan="1" colspan="1">223</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="7" rowspan="1">
                          <bold>EPA bioactive metabolome</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RvE1</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">161</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RvE2</td>
                        <td align="left" rowspan="1" colspan="1">333</td>
                        <td align="left" rowspan="1" colspan="1">199</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RvE3</td>
                        <td align="left" rowspan="1" colspan="1">333</td>
                        <td align="left" rowspan="1" colspan="1">201</td>
                        <td align="left" rowspan="1" colspan="1">0.29 ± 0.53</td>
                        <td align="left" rowspan="1" colspan="1">0.23 ± 0.19</td>
                        <td align="left" rowspan="1" colspan="1">.0794</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RvE4</td>
                        <td align="left" rowspan="1" colspan="1">333</td>
                        <td align="left" rowspan="1" colspan="1">115</td>
                        <td align="left" rowspan="1" colspan="1">0.79 ± 4.32</td>
                        <td align="left" rowspan="1" colspan="1">5.20 ± 3.04</td>
                        <td align="left" rowspan="1" colspan="1">.1627</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="7" rowspan="1">
                          <bold>AA bioactive metabolome</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">LXA<sub>4</sub>
</td>
                        <td align="left" rowspan="1" colspan="1">351</td>
                        <td align="left" rowspan="1" colspan="1">115</td>
                        <td align="left" rowspan="1" colspan="1">0.02 ± 0.05</td>
                        <td align="left" rowspan="1" colspan="1">0.06 ± 0.04</td>
                        <td align="left" rowspan="1" colspan="1">.2502</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">LXB<sub>4</sub>
</td>
                        <td align="left" rowspan="1" colspan="1">351</td>
                        <td align="left" rowspan="1" colspan="1">115</td>
                        <td align="left" rowspan="1" colspan="1">0.22 ± 0.58</td>
                        <td align="left" rowspan="1" colspan="1">0.34 ± 0.17</td>
                        <td align="left" rowspan="1" colspan="1">.2974</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">5S,15S‐diHETE</td>
                        <td align="left" rowspan="1" colspan="1">335</td>
                        <td align="left" rowspan="1" colspan="1">235</td>
                        <td align="left" rowspan="1" colspan="1">0.52 ± 1.81</td>
                        <td align="left" rowspan="1" colspan="1">1.83 ± 1.01</td>
                        <td align="left" rowspan="1" colspan="1">.2941</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">15‐epi‐LXA<sub>4</sub>
</td>
                        <td align="left" rowspan="1" colspan="1">351</td>
                        <td align="left" rowspan="1" colspan="1">115</td>
                        <td align="left" rowspan="1" colspan="1">0.06 ± 0.03</td>
                        <td align="left" rowspan="1" colspan="1">0.02 ± 0.02</td>
                        <td align="left" rowspan="1" colspan="1">.0003</td>
                        <td align="left" rowspan="1" colspan="1">***</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">15‐epi‐LXB<sub>4</sub>
</td>
                        <td align="left" rowspan="1" colspan="1">351</td>
                        <td align="left" rowspan="1" colspan="1">115</td>
                        <td align="left" rowspan="1" colspan="1">0.29 ± 1.12</td>
                        <td align="left" rowspan="1" colspan="1">0.97 ± 0.56</td>
                        <td align="left" rowspan="1" colspan="1">.3264</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">LTB<sub>4</sub>
</td>
                        <td align="left" rowspan="1" colspan="1">335</td>
                        <td align="left" rowspan="1" colspan="1">195</td>
                        <td align="left" rowspan="1" colspan="1">4.80 ± 5.91</td>
                        <td align="left" rowspan="1" colspan="1">10.83 ± 1.69</td>
                        <td align="left" rowspan="1" colspan="1">.4867</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">5S,12S‐diHETE</td>
                        <td align="left" rowspan="1" colspan="1">335</td>
                        <td align="left" rowspan="1" colspan="1">195</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1">–</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">LTC<sub>4</sub>
</td>
                        <td align="left" rowspan="1" colspan="1">626</td>
                        <td align="left" rowspan="1" colspan="1">189</td>
                        <td align="left" rowspan="1" colspan="1">0.47 ± 1.21</td>
                        <td align="left" rowspan="1" colspan="1">1.59 ± 0.40</td>
                        <td align="left" rowspan="1" colspan="1">.1950</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">LTD<sub>4</sub>
</td>
                        <td align="left" rowspan="1" colspan="1">497</td>
                        <td align="left" rowspan="1" colspan="1">189</td>
                        <td align="left" rowspan="1" colspan="1">0.22 ± 0.18</td>
                        <td align="left" rowspan="1" colspan="1">0.42 ± 0.07</td>
                        <td align="left" rowspan="1" colspan="1">.2705</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">LTE<sub>4</sub>
</td>
                        <td align="left" rowspan="1" colspan="1">440</td>
                        <td align="left" rowspan="1" colspan="1">189</td>
                        <td align="left" rowspan="1" colspan="1">0.72 ± 0.75</td>
                        <td align="left" rowspan="1" colspan="1">1.48 ± 0.12</td>
                        <td align="left" rowspan="1" colspan="1">.3629</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">PGE<sub>2</sub>
</td>
                        <td align="left" rowspan="1" colspan="1">351</td>
                        <td align="left" rowspan="1" colspan="1">189</td>
                        <td align="left" rowspan="1" colspan="1">0.02 ± 0.07</td>
                        <td align="left" rowspan="1" colspan="1">0.26 ± 0.08</td>
                        <td align="left" rowspan="1" colspan="1">.0199</td>
                        <td align="left" rowspan="1" colspan="1">*</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">PGD<sub>2</sub>
</td>
                        <td align="left" rowspan="1" colspan="1">351</td>
                        <td align="left" rowspan="1" colspan="1">189</td>
                        <td align="left" rowspan="1" colspan="1">0.03 ± 0.05</td>
                        <td align="left" rowspan="1" colspan="1">0.24 ± 0.09</td>
                        <td align="left" rowspan="1" colspan="1">.0376</td>
                        <td align="left" rowspan="1" colspan="1">*</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">PGF<sub>2a</sub>
</td>
                        <td align="left" rowspan="1" colspan="1">353</td>
                        <td align="left" rowspan="1" colspan="1">193</td>
                        <td align="left" rowspan="1" colspan="1">0.06 ± 0.08</td>
                        <td align="left" rowspan="1" colspan="1">0.21 ± 0.06</td>
                        <td align="left" rowspan="1" colspan="1">.1537</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">TxB<sub>2</sub>
</td>
                        <td align="left" rowspan="1" colspan="1">369</td>
                        <td align="left" rowspan="1" colspan="1">169</td>
                        <td align="left" rowspan="1" colspan="1">0.22 ± 0.67</td>
                        <td align="left" rowspan="1" colspan="1">8.68 ± 2.88</td>
                        <td align="left" rowspan="1" colspan="1">.0131</td>
                        <td align="left" rowspan="1" colspan="1">*</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="fsb222173-ntgp-0002">
                    <title>Note</title>
                    <fn id="fsb222173-note-0004">
                      <p>Serum was collected from healthy volunteers (<italic toggle="yes">n</italic> = 6) and patients with cardiovascular disease (<italic toggle="yes">n</italic> = 6), lipid mediators were extracted, identified and quantified using LC‐MS/MS‐based lipid mediator profiling (See methods for details). – = Below limits of quantification. Assuming non‐Gaussian distribution of the human samples, statistical analysis was determined using Mann–Whitney <italic toggle="yes">U</italic> test when comparing two groups. Data are presented as mean ± standard error of the mean. Statistical significance is indicated as *<italic toggle="yes">p</italic> &lt; .05, ***<italic toggle="yes">p</italic> &lt; .001.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <fig position="float" fig-type="FIGURE" id="fsb222173-fig-0003">
                  <label>FIGURE 3</label>
                  <caption>
                    <p>Serum lipid mediator concentrations are altered in patients with atherosclerosis versus healthy controls. Serum was collected from healthy volunteers (<italic toggle="yes">n</italic> = 6) and patients with cardiovascular disease (<italic toggle="yes">n</italic> = 6). Lipid mediators were extracted, identified and quantified using LC‐MS/MS‐based lipid mediator profiling (See methods for details). (A) Differences in lipid mediator concentrations were evaluated using PLS‐DA two‐dimensional scores plot, and (B) corresponding VIP plot of serum lipid mediators. Shaded areas represent 95% confidence interval</p>
                  </caption>
                  <graphic xlink:href="FSB2-36-0-g005" position="anchor" id="jats-graphic-5"/>
                </fig>
              </sec>
              <sec id="fsb222173-sec-0021">
                <label>3.4</label>
                <title>Lipoxin treatment significantly downregulates neutrophil CD11b expression in patients with atherosclerosis</title>
                <p>The expression of the high‐affinity state of the CD11b integrin is closely linked to the pathophysiology of atherosclerosis as it regulates chemotaxis of neutrophils and neutrophil‐platelet aggregation.<xref rid="fsb222173-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="fsb222173-bib-0045" ref-type="bibr"><sup>45</sup></xref> We measured the expression of the CD11b high‐affinity conformation on neutrophils and whether this could be altered by lipoxin treatment. As expected, all neutrophils were 100% positive for the CD11b high‐affinity conformation integrin receptor, and the MFI increased in response to fMLP stimulation on the neutrophils from both healthy controls and patients with atherosclerosis (<italic toggle="yes">p</italic> = .008 for all) (Figure <xref rid="fsb222173-fig-0004" ref-type="fig">4A</xref>). Lipoxin treatment did not alter the receptor expression at baseline in either group. The fMLP‐induced increase of CD11b expression significantly decreased in atherosclerosis patient neutrophils in response to both LXA<sub>4</sub> and LXB<sub>4</sub> (<italic toggle="yes">p</italic> = .045 and <italic toggle="yes">p</italic> &lt; .001, respectively) (Figure <xref rid="fsb222173-fig-0004" ref-type="fig">4B</xref>).</p>
                <fig position="float" fig-type="FIGURE" id="fsb222173-fig-0004">
                  <label>FIGURE 4</label>
                  <caption>
                    <p>Lipoxin‐mediated changes to the high‐affinity conformation of the CD11b receptor in human neutrophils from patients with atherosclerosis versus healthy controls. Whole blood from healthy controls (<italic toggle="yes">n</italic> = 5) or patients with atherosclerosis (<italic toggle="yes">n</italic> = 5) was exposed to inflammatory stimulus as indicated, either in the absence or presence of lipoxin A<sub>4</sub> (LXA<sub>4</sub>: 500 nM) or lipoxin B<sub>4</sub> (LXB<sub>4</sub>: 500 nM). Neutrophil expression of the CD11b high‐affinity conformation was measured by flow cytometry. (A) Neutrophil expression of the CD11b high‐affinity conformation was measured as the cellular mean fluorescence intensity (MFI). The expression was measured in controls (white bars) and patients (gray bars). The cells were untreated (Unstim.) or stimulated with chemotactic peptide N‐formyl‐Met‐Leu‐Phe (fMLP, 0.4 μM). Representative MFI histograms for CD11b expression and respective conditions are shown for controls (dashed line) and patients (solid line), where the gates were determined using a negative population (gray shaded peaks). (B) LXA<sub>4</sub> (blue bars) and LXB<sub>4</sub> (green greens)‐induced changes to the neutrophil expression of the CD11b high‐affinity conformation was calculated as the log<sub>2</sub> fold change relative to respective vehicle‐treated condition. The samples were stimulated as indicated. The bar graphs show levels of cellular CD11b MFI. Representative histograms for the expression of CD11b and respective conditions are shown for vehicle (black line), LXA<sub>4</sub> (blue line), and LXB<sub>4</sub> (green line), where the gates were determined using a negative population (gray shaded peaks). Assuming non‐Gaussian distribution of the human samples, statistical analysis was determined using Mann–Whitney <italic toggle="yes">U</italic> test when comparing two groups, and Kruskal–Wallis test with Dunn's post hoc comparisons when comparing more than two groups. Data are presented as mean ± standard error of the mean (SEM). Statistical significance is indicated as *<italic toggle="yes">p</italic> &lt; .05, **<italic toggle="yes">p</italic> &lt; .01, ***<italic toggle="yes">p</italic> &lt; .001</p>
                  </caption>
                  <graphic xlink:href="FSB2-36-0-g002" position="anchor" id="jats-graphic-7"/>
                </fig>
              </sec>
              <sec id="fsb222173-sec-0022">
                <label>3.5</label>
                <title>Lipoxin B<sub>4</sub> treatment enhances lymphatic transmigration of neutrophils from patients with atherosclerosis</title>
                <p>Leukocyte egression from the plaques plays a critical role in atherosclerosis.<xref rid="fsb222173-bib-0046" ref-type="bibr"><sup>46</sup></xref>, <xref rid="fsb222173-bib-0047" ref-type="bibr"><sup>47</sup></xref> Thus, we quantified the ability of neutrophils, isolated from either healthy controls or patients, to migrate across a monolayer of LECs in the presence or absence of a chemoattractant (IL‐8: 5 ng/ml) (schematic illustration, Figure <xref rid="fsb222173-fig-0005" ref-type="fig">5A</xref>).</p>
                <fig position="float" fig-type="FIGURE" id="fsb222173-fig-0005">
                  <label>FIGURE 5</label>
                  <caption>
                    <p>Lipoxin B<sub>4</sub> enhances the lymphatic transmigration of neutrophils from patients with atherosclerosis but does not affect neutrophils from healthy controls. Neutrophils were isolated from healthy controls or patients with atherosclerosis and added to the upper well of a transwell with a confluent lymphatic endothelial cell monolayer. The neutrophils transmigrated for three hours, after which the cells in the lower well were counted to determine the migration rate. The migration experiment was conducted using either vehicle or the chemoattractant interleukin (IL)‐8 (5 ng/ml) in the lower well. (A) A schematic illustration of the transmigration assay is shown. (B) The percentage of neutrophils that migrated across lymphatic endothelial cell monolayer were quantified, either spontaneously or in response to the chemoattractant IL‐8. The migration pattern was investigated in neutrophils isolated from healthy controls (<italic toggle="yes">n</italic> = 6, white bars) and patients with atherosclerosis (<italic toggle="yes">n</italic> = 6, gray bars). (C) Neutrophils were treated with vehicle (0.01% ethanol), lipoxin A<sub>4</sub> (LXA<sub>4</sub>:1 nM, blue bars), or lipoxin B<sub>4</sub> (LXB<sub>4</sub>: 1 nM, green bars) for 15 minutes prior to the transmigration assay. Lipoxin‐induced changes to the neutrophil migration rate were calculated as the log<sub>2</sub> fold change relative to respective vehicle‐treated condition. Assuming non‐Gaussian distribution of the human samples, statistical analysis was determined using Mann–Whitney <italic toggle="yes">U</italic> test when comparing two groups, and Kruskal–Wallis test with Dunn's post hoc comparisons when comparing over two groups. Data are presented as mean ± standard error of the mean (SEM). Statistical significance is indicated as *<italic toggle="yes">p</italic> &lt; .05, **<italic toggle="yes">p</italic> &lt; .01</p>
                  </caption>
                  <graphic xlink:href="FSB2-36-0-g001" position="anchor" id="jats-graphic-9"/>
                </fig>
                <p>There was no difference in spontaneous transmigration of neutrophils from controls or patients (Figure <xref rid="fsb222173-fig-0005" ref-type="fig">5B</xref>). In healthy controls, IL‐8 significantly enhanced the rate of neutrophil migration across the LEC monolayer (<italic toggle="yes">p</italic> = .002). Neutrophils isolated from patients with atherosclerosis tended to migrate to a lesser extent than healthy controls, although there was not a significant difference between the groups (Figure <xref rid="fsb222173-fig-0005" ref-type="fig">5B</xref>).</p>
                <p>To investigate if SPMs could modulate the lymphatic transmigration, isolated neutrophils were treated with vehicle (0.01% ethanol) or lipoxins (1 nM) for 15 min prior to the migration assay. The lipoxins did not affect the migration of neutrophils isolated from healthy controls (Figure <xref rid="fsb222173-fig-0005" ref-type="fig">5C</xref>). However, neutrophils isolated from patients with atherosclerosis responded to LXB<sub>4</sub> treatment with a significantly increased transmigration across the lymphatic monolayer (<italic toggle="yes">p</italic> = .0235) (Figure <xref rid="fsb222173-fig-0005" ref-type="fig">5C</xref>).</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="fsb222173-sec-0023">
              <label>4</label>
              <title>DISCUSSION</title>
              <p>Mortality related to cardiovascular disease accounted for a third of deaths globally (18.5 million lives) in 2019, indicating the pressing need for effective therapeutics.<xref rid="fsb222173-bib-0048" ref-type="bibr"><sup>48</sup></xref> It is well established that inflammation fuels the development of atherosclerosis.<xref rid="fsb222173-bib-0002" ref-type="bibr"><sup>2</sup></xref>, <xref rid="fsb222173-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="fsb222173-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="fsb222173-bib-0049" ref-type="bibr"><sup>49</sup></xref>, <xref rid="fsb222173-bib-0050" ref-type="bibr"><sup>50</sup></xref>, <xref rid="fsb222173-bib-0051" ref-type="bibr"><sup>51</sup></xref> Thus, attenuating inflammation has emerged as a promising anti‐atherogenic therapeutic strategy,<xref rid="fsb222173-bib-0003" ref-type="bibr"><sup>3</sup></xref> in addition to standard clinical care with lipid‐lowering medication. For instance, the Canakinumab Anti‐inflammatory Thrombosis Outcome Study, CANTOS, presented evidence that attenuating the levels of the pro‐inflammatory cytokine IL‐1β reduced nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death; an effect independent of the patients’ LDL/HDL levels.<xref rid="fsb222173-bib-0052" ref-type="bibr"><sup>52</sup></xref>, <xref rid="fsb222173-bib-0053" ref-type="bibr"><sup>53</sup></xref> However, the Canakinumab‐mediated effect varied significantly between subgroups, and furthermore, these anti‐inflammatory drugs may increase susceptibility to infections.<xref rid="fsb222173-bib-0052" ref-type="bibr"><sup>52</sup></xref>, <xref rid="fsb222173-bib-0053" ref-type="bibr"><sup>53</sup></xref> An alternative approach to attenuate chronic pro‐atherogenic inflammation is to enhance endogenous pathways that promote the resolution of inflammation.<xref rid="fsb222173-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="fsb222173-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="fsb222173-bib-0054" ref-type="bibr"><sup>54</sup></xref>, <xref rid="fsb222173-bib-0055" ref-type="bibr"><sup>55</sup></xref> The strategy of boosting resolution through administration of exogenous SPMs has been shown to reduce the risk of cardiovascular disease in experimental models,<xref rid="fsb222173-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="fsb222173-bib-0019" ref-type="bibr"><sup>19</sup></xref>, <xref rid="fsb222173-bib-0020" ref-type="bibr"><sup>20</sup></xref>, <xref rid="fsb222173-bib-0021" ref-type="bibr"><sup>21</sup></xref>, <xref rid="fsb222173-bib-0022" ref-type="bibr"><sup>22</sup></xref>, <xref rid="fsb222173-bib-0023" ref-type="bibr"><sup>23</sup></xref>, <xref rid="fsb222173-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="fsb222173-bib-0025" ref-type="bibr"><sup>25</sup></xref>, <xref rid="fsb222173-bib-0026" ref-type="bibr"><sup>26</sup></xref>, <xref rid="fsb222173-bib-0027" ref-type="bibr"><sup>27</sup></xref> and some evidence suggests that these findings may translate to humans.<xref rid="fsb222173-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="fsb222173-bib-0028" ref-type="bibr"><sup>28</sup></xref> Herein, we demonstrate the potent anti‐atherogenic effects of lipoxins on human neutrophils from patients with atherosclerosis, which differs from the effects in healthy controls.</p>
              <p>Neutrophil ROS production plays a critical role in the antibacterial host defense,<xref rid="fsb222173-bib-0035" ref-type="bibr"><sup>35</sup></xref>, <xref rid="fsb222173-bib-0044" ref-type="bibr"><sup>44</sup></xref> although an uncontrolled continuous oxidative burst response can be detrimental. We demonstrate that neutrophils isolated from patients with atherosclerosis produce significantly more ROS than cells from healthy controls, both at baseline and on stimulation with fMLP or <italic toggle="yes">E. coli</italic>. This is likely due to these patients’ elevated C‐reactive protein levels, which may prime the respiratory burst response and sustain inflammation.<xref rid="fsb222173-bib-0035" ref-type="bibr"><sup>35</sup></xref> In patients with atherosclerosis, we also demonstrated that treating whole blood with lipoxins reduced the excessive ROS production elicited by the inflammatory triggers. In support of these findings, we have previously demonstrated that LXA<sub>4</sub> treatment reduces <italic toggle="yes">Porphyromonas gingivalis</italic>–induced leukocyte ROS production in human whole blood.<xref rid="fsb222173-bib-0010" ref-type="bibr"><sup>10</sup></xref> Reduced ROS production after LXA<sub>4</sub> treatment has also been observed in other cell types following various inflammatory challenges in vitro, for example, in endothelial,<xref rid="fsb222173-bib-0056" ref-type="bibr"><sup>56</sup></xref>, <xref rid="fsb222173-bib-0057" ref-type="bibr"><sup>57</sup></xref> pancreatic,<xref rid="fsb222173-bib-0058" ref-type="bibr"><sup>58</sup></xref> and microglia<xref rid="fsb222173-bib-0059" ref-type="bibr"><sup>59</sup></xref> cell lines. As elevated ROS production may promote leukocyte infiltration, plaque development, and plaque rupture,<xref rid="fsb222173-bib-0033" ref-type="bibr"><sup>33</sup></xref>, <xref rid="fsb222173-bib-0060" ref-type="bibr"><sup>60</sup></xref> an SPM‐mediated attenuation may benefit patients with atherosclerosis. Our data concomitantly show that lipoxin treatment enhanced fMLP‐ and <italic toggle="yes">E. coli</italic>–induced ROS production from neutrophils of healthy controls, with LXB<sub>4</sub> having a more significant effect. The lipoxin‐induced manipulation of <italic toggle="yes">E. coli</italic>–induced ROS in healthy controls was not related to an increased phagocytosis rate. Published data on the effect of SPMs in healthy controls are sparse. However, one study demonstrated that LXA<sub>4</sub> treatment of healthy Wistar rat aorta led to an increase in ROS production ex vivo.<xref rid="fsb222173-bib-0061" ref-type="bibr"><sup>61</sup></xref> Thus, it is plausible that lipoxins can upregulate ROS production in healthy individuals, which may be beneficial given that an efficient, but controlled, oxidative burst response is required by the immune system. In conclusion, we found that neutrophils from patients with atherosclerosis displayed an excessive oxidative burst response when activated, compared with neutrophils from healthy controls. Our findings demonstrate that the lipoxin‐mediated effect on ROS production differs in health versus disease. Lipoxins only attenuate the oxidative burst response if cells are derived from an inflammatory environment, for instance, in the patients with atherosclerosis who have elevated systemic inflammation. This is important to consider when pursuing the therapeutic application of SPMs, as their effect may differ depending on the inflammatory status of the individual patient.</p>
              <p>SPMs exert their biological effects through the action of G‐coupled protein receptors, for example, ALX/FPR2, ERV1/ChemR23, DRV1/GPR32, and DRV2/GPR18,<xref rid="fsb222173-bib-0005" ref-type="bibr"><sup>5</sup></xref>, <xref rid="fsb222173-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="fsb222173-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="fsb222173-bib-0062" ref-type="bibr"><sup>62</sup></xref> although the LXB<sub>4</sub> receptor remains to be identified. Characterizing the expression of these receptors in health and disease may provide important mechanistic clues of inflammatory resolution, and these receptors may also represent therapeutic targets. However, it is noteworthy that pro‐inflammatory ligands also activate some of these receptors, and conflicting findings regarding the regulation of these receptors in human atherosclerosis have been reported.<xref rid="fsb222173-bib-0055" ref-type="bibr"><sup>55</sup></xref> We focused our investigations on the expression of the main LXA<sub>4</sub> receptor FPR2/ALX.<xref rid="fsb222173-bib-0009" ref-type="bibr"><sup>9</sup></xref> FPR2/ALX is a pluripotent receptor that recognizes both pro‐resolving (e.g., LXA<sub>4</sub> and annexin A1) and pro‐inflammatory (e.g., fMLP) signals and elicits different responses depending on the ligand and the subsequent conformational change of the receptor.<xref rid="fsb222173-bib-0063" ref-type="bibr"><sup>63</sup></xref>, <xref rid="fsb222173-bib-0064" ref-type="bibr"><sup>64</sup></xref> These effects include altered leukocyte chemotaxis, cytokine production, and efferocytosis.<xref rid="fsb222173-bib-0065" ref-type="bibr"><sup>65</sup></xref>, <xref rid="fsb222173-bib-0066" ref-type="bibr"><sup>66</sup></xref>, <xref rid="fsb222173-bib-0067" ref-type="bibr"><sup>67</sup></xref> In mouse models, FPR2/ALX receptor knockouts are characterized by delayed atherosclerosis development.<xref rid="fsb222173-bib-0019" ref-type="bibr"><sup>19</sup></xref> In humans, FPR2/ALX expression is increased in atherosclerotic plaques.<xref rid="fsb222173-bib-0019" ref-type="bibr"><sup>19</sup></xref> We observed no difference in the neutrophil FPR2/ALX expression in either group at baseline. Neutrophil FPR2/ALX expression was reduced by fMLP in both groups. As a measurement of endogenous resolution we also quantified serum levels of SPMs in healthy controls and patients with atherosclerosis. MCTR3 and 15‐epi LXA<sub>4</sub> were identified as the main mediators that drive the separation observed between healthy controls and patients with atherosclerosis. MCTR3 is a peptide–lipid‐conjugated mediator previously shown to have potent pro‐resolving properties, for instance upregulating human neutrophil and macrophage phagocytic responses.<xref rid="fsb222173-bib-0068" ref-type="bibr"><sup>68</sup></xref> Thus, the fact that the patient cohort has reduced levels of the pro‐resolving factor MCTR3 may indicate reduced resolution capability of this group. The elevated levels of 15‐epi LXA<sub>4</sub> observed in the patient cohort may be explained by the fact that these individuals were treated with low‐dose aspirin and statins, as these drugs induce the formation of epi‐lipoxins.<xref rid="fsb222173-bib-0069" ref-type="bibr"><sup>69</sup></xref>, <xref rid="fsb222173-bib-0070" ref-type="bibr"><sup>70</sup></xref>, <xref rid="fsb222173-bib-0071" ref-type="bibr"><sup>71</sup></xref> We would like to point out that the concentrations of this mediator are in line with concentrations observed for many other lipid mediators in these samples. Lipid mediator concentrations in samples are dependent on a number of factors that include substrate availability, activation status of the cells carrying the biosynthetic enzymes as well as their expression levels and activities, and the expression and activity of enzymes involved in their further metabolism. Our analysis only offers a snapshot of this very dynamic process. Nonetheless, concentrations of both 15‐epi LXA<sub>4</sub> and those of another aspirin‐triggered SPM, 17R‐PD1, were both increased in samples from patients with atherosclerosis, in line with the known role of aspirin to upregulate these autacoids. In summary, we did not find any evidence indicating that neutrophil surface expression of the lipoxin receptor FPR2/ALX was altered in the atherosclerotic cohort, but lipid mediator profiling analyses revealed that the endogenous resolution capacity may be altered in atherosclerosis.</p>
              <p>The integrin complex CD11b/CD18 is expressed by many leukocyte subsets and is important in several biological processes related to atherosclerosis.<xref rid="fsb222173-bib-0010" ref-type="bibr"><sup>10</sup></xref> In addition to regulating leukocyte transendothelial migration, CD11b/CD18 mediates platelet–leukocyte aggregation and associated ROS production by binding to the platelet GPIIb/IIIa receptor via fibrinogen.<xref rid="fsb222173-bib-0010" ref-type="bibr"><sup>10</sup></xref> Previously, we have demonstrated that lipoxins can reduce <italic toggle="yes">P. gingivalis</italic>–induced thrombotic events in human blood by manipulating the neutrophil expression of both the total CD11b/CD18 integrin complex and the upregulation of its high‐affinity conformation.<xref rid="fsb222173-bib-0010" ref-type="bibr"><sup>10</sup></xref> In this study, we found no differences in the CD11b high‐affinity conformation expression comparing controls with patients in response to inflammatory stimuli. However, LXA<sub>4</sub> and LXB<sub>4</sub> treatment reduced the fMLP‐induced upregulation of the CD11b high‐affinity conformation in patients with atherosclerosis, although not in healthy controls. This again highlights the possibility that lipoxins exert their actions in a manner tailored to the needs of the individual.</p>
              <p>Lymphatic dysfunction precedes atherosclerosis, and stimulation of lymphangiogenesis limits plaque formation and improves inflammatory cell migration through the lymphatics.<xref rid="fsb222173-bib-0072" ref-type="bibr"><sup>72</sup></xref> The lymphatics play an important role in reverse cholesterol transport, macromolecule clearance, and immune cell egression in atherosclerosis.<xref rid="fsb222173-bib-0073" ref-type="bibr"><sup>73</sup></xref>, <xref rid="fsb222173-bib-0074" ref-type="bibr"><sup>74</sup></xref> Thus, we investigated the migratory capacity of neutrophils from patients and healthy controls in an ex vivo transmigration assay with human LECs. We demonstrated that neutrophils from patients with atherosclerosis moved at a slower rate across lymphatic endothelium than controls. LXB<sub>4</sub> treatment significantly increased the lymphatic neutrophil transmigration from patients with atherosclerosis, but lipoxins did not affect the migration of neutrophils from controls. Future studies are needed to determine the mechanism of how LXB<sub>4</sub> restoration of lymphatic transmigration in neutrophils from patients is mediated. We hypothesize that the role of LXB<sub>4</sub> on neutrophil migration may be of high relevance in atherosclerosis.</p>
              <p>In conclusion, we have evaluated the effects of lipoxins on the function of neutrophils isolated from patients with atherosclerosis compared with neutrophils from healthy controls. Patients demonstrated altered endogenous SPM production and lipoxins attenuated neutrophil oxidative burst, a key driver of the atherosclerotic process, in the patient cohort. Importantly, this effect was restricted to neutrophils from patients with atherosclerosis. Conversely, in neutrophils from healthy controls, lipoxins increased the oxidative burst, indicating that the lipoxin effect depends on the inflammatory status of the individual. In neutrophils from patients with atherosclerosis, lipoxins also reduced upregulation of the high‐affinity conformation of the CD11b integrin, which has a central role in clot activation. Finally, LXB<sub>4</sub> enhanced the lymphatic transmigration of human neutrophils isolated from atherosclerosis patients across LECs ex vivo, which may translate to a pro‐resolving effect of enhanced lymphatic egression. Although both lipoxins modulated neutrophil function in most assays investigated, LXB<sub>4</sub> displayed more potent effects than LXA<sub>4</sub>. This study highlights the therapeutic potential of lipoxins in atherosclerosis and demonstrates that the pro‐resolving effect of lipoxins is related to the individual's inflammatory status.</p>
            </sec>
            <sec sec-type="COI-statement" id="fsb222173-sec-0025">
              <title>DISCLOSURES</title>
              <p>All the authors declare that they have no competing interests.</p>
            </sec>
            <sec id="fsb222173-sec-0026">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p>Emma Börgeson, Jamie D. Kraft, Robert Blomgran, Ida Bergström, Sofia Nyström, and Per Skoog were involved in conception and study design. Jamie D. Kraft, Robert Blomgran, Ida Bergström, Matúš Soták, Madison Clark, and Jesmond Dalli performed the experiments and data analysis. Per Skoog was medically responsible for the clinical recruitment of patients, and the patient samples were collected and processed by Jamie D. Kraft, Alankrita Rani, Meenu Rohini Rajan, Matúš Soták, and Catherine Åhlund. All authors contributed to the writing and editing of the manuscript and the interpretation of data.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="fsb222173-sup-0001" position="float" content-type="local-data">
                <caption>
                  <p>Fig S1</p>
                </caption>
                <media xlink:href="FSB2-36-0-s003.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="fsb222173-sup-0002" position="float" content-type="local-data">
                <caption>
                  <p>Fig S2</p>
                </caption>
                <media xlink:href="FSB2-36-0-s001.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="fsb222173-sup-0003" position="float" content-type="local-data">
                <caption>
                  <p>Fig S3</p>
                </caption>
                <media xlink:href="FSB2-36-0-s004.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="fsb222173-sup-0004" position="float" content-type="local-data">
                <caption>
                  <p>Text S1</p>
                </caption>
                <media xlink:href="FSB2-36-0-s002.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="fsb222173-sec-0024">
              <title>ACKNOWLEDGMENTS</title>
              <p>We gratefully acknowledge the contribution of Catherine Åhlund, who was responsible for organizing the collection of clinical material. The research was funded by the Wallenberg Centre for Molecular &amp; Translational Medicine at University of Gothenburg and Knut &amp; Alice Wallenberg Foundation, the Swedish Research Council (#2016/82), SSMF (#S150086), and an ERC StG (#804418) and grant support from NIH (#R37AI062765#).</p>
            </ack>
            <sec sec-type="data-availability" id="fsb222173-sec-0028">
              <title>Data Availability Statement</title>
              <p>All raw data (lipdomics, flow cytometry, transmigration and clinical characteristics data) that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.</p>
            </sec>
            <ref-list content-type="cited-references" id="fsb222173-bibl-0001">
              <title>REFERENCES</title>
              <ref id="fsb222173-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0001"><string-name><surname>Bäck</surname><given-names>M</given-names></string-name>, <string-name><surname>Yurdagul</surname><given-names>A</given-names></string-name>, <string-name><surname>Tabas</surname><given-names>I</given-names></string-name>, <string-name><surname>Öörni</surname><given-names>K</given-names></string-name>, <string-name><surname>Kovanen</surname><given-names>PT</given-names></string-name>. <article-title>Inflammation and its resolution in atherosclerosis: Mediators and therapeutic opportunities</article-title>. <source>Nat Rev Cardiol</source>. <year>2019</year>;<volume>16</volume>:<fpage>389</fpage>‐<lpage>406</lpage>.<pub-id pub-id-type="pmid">30846875</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0002"><string-name><surname>Libby</surname><given-names>P</given-names></string-name>, <string-name><surname>Ridker</surname><given-names>PM</given-names></string-name>, <string-name><surname>Maseri</surname><given-names>A</given-names></string-name>. <article-title>Inflammation and atherosclerosis</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>105</volume>:<fpage>1135</fpage>‐<lpage>1143</lpage>.<pub-id pub-id-type="pmid">11877368</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0003"><string-name><surname>Fredman</surname><given-names>G</given-names></string-name>, <string-name><surname>Tabas</surname><given-names>I</given-names></string-name>. <article-title>Boosting inflammation resolution in atherosclerosis: the next frontier for therapy</article-title>. <source>Am J Pathol</source>. <year>2017</year>;<volume>187</volume>:<fpage>1211</fpage>‐<lpage>1221</lpage>.<pub-id pub-id-type="pmid">28527709</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0004"><string-name><surname>Kasikara</surname><given-names>C</given-names></string-name>, <string-name><surname>Doran</surname><given-names>AC</given-names></string-name>, <string-name><surname>Cai</surname><given-names>B</given-names></string-name>, <string-name><surname>Tabas</surname><given-names>I</given-names></string-name>. <article-title>The role of non‐resolving inflammation in atherosclerosis</article-title>. <source>J Clin Invest</source>. <year>2018</year>;<volume>128</volume>:<fpage>2713</fpage>‐<lpage>2723</lpage>.<pub-id pub-id-type="pmid">30108191</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0005"><string-name><surname>Serhan</surname><given-names>CN</given-names></string-name>. <article-title>Pro‐resolving lipid mediators are leads for resolution physiology</article-title>. <source>Nature</source>. <year>2014</year>;<volume>510</volume>:<fpage>92</fpage>‐<lpage>101</lpage>.<pub-id pub-id-type="pmid">24899309</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0006"><string-name><surname>Titos</surname><given-names>E</given-names></string-name>, <string-name><surname>Claria</surname><given-names>J</given-names></string-name>. <article-title>Omega‐3‐derived mediators counteract obesity‐induced adipose tissue inflammation</article-title>. <source>Prostaglandins Other Lipid Mediat</source>. <year>2013</year>;<volume>107</volume>:<fpage>77</fpage>‐<lpage>84</lpage>.<pub-id pub-id-type="pmid">23707933</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0007"><string-name><surname>Vasconcelos</surname><given-names>DP</given-names></string-name>, <string-name><surname>Costa</surname><given-names>M</given-names></string-name>, <string-name><surname>Amaral</surname><given-names>IF</given-names></string-name>, <string-name><surname>Barbosa</surname><given-names>MA</given-names></string-name>, <string-name><surname>Aguas</surname><given-names>AP</given-names></string-name>, <string-name><surname>Barbosa</surname><given-names>JN</given-names></string-name>. <article-title>Modulation of the inflammatory response to chitosan through M2 macrophage polarization using pro‐resolution mediators</article-title>. <source>Biomaterials</source>. <year>2015</year>;<volume>37</volume>:<fpage>116</fpage>‐<lpage>123</lpage>.<pub-id pub-id-type="pmid">25453942</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0008"><string-name><surname>Tabas</surname><given-names>I</given-names></string-name>, <string-name><surname>Glass</surname><given-names>CK</given-names></string-name>. <article-title>Anti‐inflammatory therapy in chronic disease: challenges and opportunities</article-title>. <source>Science</source>. <year>2013</year>;<volume>339</volume>:<fpage>166</fpage>‐<lpage>172</lpage>.<pub-id pub-id-type="pmid">23307734</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0009"><string-name><surname>Chandrasekharan</surname><given-names>JA</given-names></string-name>, <string-name><surname>Sharma‐Walia</surname><given-names>N</given-names></string-name>. <article-title>Lipoxins: nature's way to resolve inflammation</article-title>. <source>J Inflamm Res</source>. <year>2015</year>;<volume>8</volume>:<fpage>181</fpage>‐<lpage>192</lpage>.<pub-id pub-id-type="pmid">26457057</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0010"><string-name><surname>Borgeson</surname><given-names>E</given-names></string-name>, <string-name><surname>Lonn</surname><given-names>J</given-names></string-name>, <string-name><surname>Bergstrom</surname><given-names>I</given-names></string-name>, et al. <article-title>Lipoxin A(4) inhibits porphyromonas gingivalis‐induced aggregation and reactive oxygen species production by modulating neutrophil‐platelet interaction and CD11b expression</article-title>. <source>Infect Immun</source>. <year>2011</year>;<volume>79</volume>:<fpage>1489</fpage>‐<lpage>1497</lpage>.<pub-id pub-id-type="pmid">21263017</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0011"><string-name><surname>Borgeson</surname><given-names>E</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>AM</given-names></string-name>, <string-name><surname>Lee</surname><given-names>YS</given-names></string-name>, et al. <article-title>Lipoxin A<sub>4</sub> attenuates obesity‐induced adipose inflammation and associated liver and kidney disease</article-title>. <source>Cell Metab</source>. <year>2015</year>;<volume>22</volume>:<fpage>125</fpage>‐<lpage>137</lpage>.<pub-id pub-id-type="pmid">26052006</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0012"><string-name><surname>Serhan</surname><given-names>CN</given-names></string-name>. <article-title>Discovery of specialized pro‐resolving mediators marks the dawn of resolution physiology and pharmacology</article-title>. <source>Mol Aspects Med</source>. <year>2017</year>;<volume>58</volume>:<fpage>1</fpage>‐<lpage>11</lpage>.<pub-id pub-id-type="pmid">28263773</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0013"><string-name><surname>Serhan</surname><given-names>CN</given-names></string-name>, <string-name><surname>Chiang</surname><given-names>N</given-names></string-name>, <string-name><surname>Dalli</surname><given-names>J</given-names></string-name>, <string-name><surname>Levy</surname><given-names>BD</given-names></string-name>. <article-title>Lipid mediators in the resolution of inflammation</article-title>. <source>Cold Spring Harb Perspect Biol</source>. <year>2014</year>;<volume>7</volume>:<elocation-id>a016311</elocation-id>.<pub-id pub-id-type="pmid">25359497</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0014"><string-name><surname>Headland</surname><given-names>SE</given-names></string-name>, <string-name><surname>Norling</surname><given-names>LV</given-names></string-name>. <article-title>The resolution of inflammation: Principles and challenges</article-title>. <source>Semin Immunol</source>. <year>2015</year>;<volume>27</volume>:<fpage>149</fpage>‐<lpage>160</lpage>.<pub-id pub-id-type="pmid">25911383</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0015"><string-name><surname>Serhan</surname><given-names>CN</given-names></string-name>. <article-title>Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms</article-title>. <source>FASEB J</source>. <year>2017</year>;<volume>31</volume>:<fpage>1273</fpage>‐<lpage>1288</lpage>.<pub-id pub-id-type="pmid">28087575</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0016"><string-name><surname>Börgeson</surname><given-names>E</given-names></string-name>, <string-name><surname>McGillicuddy</surname><given-names>FC</given-names></string-name>, <string-name><surname>Harford</surname><given-names>KA</given-names></string-name>, et al. <article-title>Lipoxin A<sub>4</sub> attenuates adipose inflammation</article-title>. <source>FASEB J</source>. <year>2012</year>;<volume>26</volume>:<fpage>4287</fpage>‐<lpage>4294</lpage>.<pub-id pub-id-type="pmid">22700871</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0017"><string-name><surname>Borgeson</surname><given-names>E</given-names></string-name>, <string-name><surname>Docherty</surname><given-names>NG</given-names></string-name>, <string-name><surname>Murphy</surname><given-names>M</given-names></string-name>, et al. <article-title>Lipoxin A(4) and benzo‐lipoxin A(4) attenuate experimental renal fibrosis</article-title>. <source>FASEB J</source>. <year>2011</year>;<volume>25</volume>:<fpage>2967</fpage>‐<lpage>2979</lpage>.<pub-id pub-id-type="pmid">21628447</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0018"><string-name><surname>Fredman</surname><given-names>G</given-names></string-name>, <string-name><surname>Hellmann</surname><given-names>J</given-names></string-name>, <string-name><surname>Proto</surname><given-names>JD</given-names></string-name>, et al. <article-title>An imbalance between specialized pro‐resolving lipid mediators and pro‐inflammatory leukotrienes promotes instability of atherosclerotic plaques</article-title>. <source>Nat Commun</source>. <year>2016</year>;<volume>7</volume>:<elocation-id>12859</elocation-id>.<pub-id pub-id-type="pmid">27659679</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0019"><string-name><surname>Petri</surname><given-names>MH</given-names></string-name>, <string-name><surname>Laguna‐Fernandez</surname><given-names>A</given-names></string-name>, <string-name><surname>Gonzalez‐Diez</surname><given-names>M</given-names></string-name>, <string-name><surname>Paulsson‐Berne</surname><given-names>G</given-names></string-name>, <string-name><surname>Hansson</surname><given-names>GK</given-names></string-name>, <string-name><surname>Back</surname><given-names>M</given-names></string-name>. <article-title>The role of the FPR2/ALX receptor in atherosclerosis development and plaque stability</article-title>. <source>Cardiovasc Res</source>. <year>2015</year>;<volume>105</volume>:<fpage>65</fpage>‐<lpage>74</lpage>.<pub-id pub-id-type="pmid">25341894</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0020"><string-name><surname>Petri</surname><given-names>MH</given-names></string-name>, <string-name><surname>Laguna‐Fernandez</surname><given-names>A</given-names></string-name>, <string-name><surname>Arnardottir</surname><given-names>H</given-names></string-name>, et al. <article-title>Aspirin‐triggered lipoxin A<sub>4</sub> inhibits atherosclerosis progression in apolipoprotein E−/− mice</article-title>. <source>Br J Pharmacol</source>. <year>2017</year>;<volume>174</volume>:<fpage>4043</fpage>‐<lpage>4054</lpage>.<pub-id pub-id-type="pmid">28071789</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0021"><string-name><surname>Petri</surname><given-names>MH</given-names></string-name>, <string-name><surname>Laguna‐Fernandez</surname><given-names>A</given-names></string-name>, <string-name><surname>Tseng</surname><given-names>C‐N</given-names></string-name>, <string-name><surname>Hedin</surname><given-names>U</given-names></string-name>, <string-name><surname>Perretti</surname><given-names>M</given-names></string-name>, <string-name><surname>Bäck</surname><given-names>M</given-names></string-name>. <article-title>Aspirin‐triggered 15‐epi‐lipoxin A₄ signals through FPR2/ALX in vascular smooth muscle cells and protects against intimal hyperplasia after carotid ligation</article-title>. <source>Int J Cardiol</source>. <year>2015</year>;<volume>179</volume>:<fpage>370</fpage>‐<lpage>372</lpage>.<pub-id pub-id-type="pmid">25464488</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0022"><string-name><surname>Fredman</surname><given-names>G</given-names></string-name>, <string-name><surname>Kamaly</surname><given-names>N</given-names></string-name>, <string-name><surname>Spolitu</surname><given-names>S</given-names></string-name>, et al. <article-title>Targeted nanoparticles containing the proresolving peptide Ac2‐26 protect against advanced atherosclerosis in hypercholesterolemic mice</article-title>. <source>Sci Transl Med</source>. <year>2015</year>;<volume>7</volume>:<fpage>220</fpage>‐<lpage>275</lpage>.</mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0023"><string-name><surname>Drechsler</surname><given-names>M</given-names></string-name>, <string-name><surname>Jong</surname><given-names>R</given-names></string-name>, <string-name><surname>Rossaint</surname><given-names>J</given-names></string-name>, et al. <article-title>Annexin A1 counteracts chemokine‐induced arterial myeloid cell recruitment</article-title>. <source>Circ Res</source>. <year>2015</year>;<volume>116</volume>:<fpage>827</fpage>‐<lpage>835</lpage>.<pub-id pub-id-type="pmid">25520364</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0024"><string-name><surname>Viola</surname><given-names>JR</given-names></string-name>, <string-name><surname>Lemnitzer</surname><given-names>P</given-names></string-name>, <string-name><surname>Jansen</surname><given-names>Y</given-names></string-name>, et al. <article-title>Resolving lipid mediators Maresin 1 and Resolvin D2 prevent atheroprogression in mice</article-title>. <source>Circ Res</source>. <year>2016</year>;<volume>119</volume>:<fpage>1030</fpage>‐<lpage>1038</lpage>.<pub-id pub-id-type="pmid">27531933</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0025"><string-name><surname>Hasturk</surname><given-names>H</given-names></string-name>, <string-name><surname>Abdallah</surname><given-names>R</given-names></string-name>, <string-name><surname>Kantarci</surname><given-names>A</given-names></string-name>, et al. <article-title>Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation‐induced atherogenesis</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2015</year>;<volume>35</volume>:<fpage>1123</fpage>‐<lpage>1133</lpage>.<pub-id pub-id-type="pmid">25792445</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0026"><string-name><surname>Salic</surname><given-names>K</given-names></string-name>, <string-name><surname>Morrison</surname><given-names>MC</given-names></string-name>, <string-name><surname>Verschuren</surname><given-names>L</given-names></string-name>, et al. <article-title>Resolvin E1 attenuates atherosclerosis in absence of cholesterol‐lowering effects and on top of atorvastatin</article-title>. <source>Atherosclerosis</source>. <year>2016</year>;<volume>250</volume>:<fpage>158</fpage>‐<lpage>165</lpage>.<pub-id pub-id-type="pmid">27236706</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0027"><string-name><surname>Liu</surname><given-names>G</given-names></string-name>, <string-name><surname>Gong</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>R</given-names></string-name>, et al. <article-title>Resolvin E1 attenuates injury‐induced vascular neointimal formation by inhibition of inflammatory responses and vascular smooth muscle cell migration</article-title>. <source>FASEB J</source>. <year>2018</year>;<volume>32</volume>:<fpage>5413</fpage>‐<lpage>5425</lpage>.<pub-id pub-id-type="pmid">29723062</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0028"><string-name><surname>Brennan</surname><given-names>EP</given-names></string-name>, <string-name><surname>Mohan</surname><given-names>M</given-names></string-name>, <string-name><surname>McClelland</surname><given-names>A</given-names></string-name>, et al. <article-title>Lipoxins protect against inflammation in diabetes‐associated atherosclerosis</article-title>. <source>Diabetes</source>. <year>2018</year>;<volume>67</volume>:<fpage>2657</fpage>‐<lpage>2667</lpage>.<pub-id pub-id-type="pmid">30213823</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0029"><string-name><surname>Thul</surname><given-names>S</given-names></string-name>, <string-name><surname>Labat</surname><given-names>C</given-names></string-name>, <string-name><surname>Temmar</surname><given-names>M</given-names></string-name>, <string-name><surname>Benetos</surname><given-names>A</given-names></string-name>, <string-name><surname>Bäck</surname><given-names>M</given-names></string-name>. <article-title>Low salivary resolvin D1 to leukotriene B<sub>4</sub> ratio predicts carotid intima media thickness: A novel biomarker of non‐resolving vascular inflammation</article-title>. <source>Eur J Prev Cardiol</source>. <year>2020</year>;<volume>24</volume>:<fpage>903</fpage>‐<lpage>906</lpage>.</mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0030"><string-name><surname>Ionita</surname><given-names>MG</given-names></string-name>, <string-name><surname>van den Borne</surname><given-names>P</given-names></string-name>, <string-name><surname>Catanzariti</surname><given-names>LM</given-names></string-name>, et al. <article-title>High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture‐prone lesions</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2010</year>;<volume>30</volume>:<fpage>1842</fpage>‐<lpage>1848</lpage>.<pub-id pub-id-type="pmid">20595650</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0031"><string-name><surname>Drechsler</surname><given-names>M</given-names></string-name>, <string-name><surname>Döring</surname><given-names>Y</given-names></string-name>, <string-name><surname>Megens</surname><given-names>RT</given-names></string-name>, <string-name><surname>Soehnlein</surname><given-names>O</given-names></string-name>. <article-title>Neutrophilic granulocytes ‐ promiscuous accelerators of atherosclerosis</article-title>. <source>Thromb Haemost</source>. <year>2011</year>;<volume>106</volume>:<fpage>839</fpage>‐<lpage>848</lpage>.<pub-id pub-id-type="pmid">22012406</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0032"><string-name><surname>Silvestre‐Roig</surname><given-names>C</given-names></string-name>, <string-name><surname>Braster</surname><given-names>Q</given-names></string-name>, <string-name><surname>Ortega‐Gomez</surname><given-names>A</given-names></string-name>, <string-name><surname>Soehnlein</surname><given-names>O</given-names></string-name>. <article-title>Neutrophils as regulators of cardiovascular inflammation</article-title>. <source>Nat Rev Cardiol</source>. <year>2020</year>;<volume>17</volume>:<fpage>327</fpage>‐<lpage>340</lpage>.<pub-id pub-id-type="pmid">31996800</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0033"><string-name><surname>Döring</surname><given-names>Y</given-names></string-name>, <string-name><surname>Drechsler</surname><given-names>M</given-names></string-name>, <string-name><surname>Soehnlein</surname><given-names>O</given-names></string-name>, <string-name><surname>Weber</surname><given-names>C</given-names></string-name>. <article-title>Neutrophils in atherosclerosis</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2015</year>;<volume>35</volume>:<fpage>288</fpage>‐<lpage>295</lpage>.<pub-id pub-id-type="pmid">25147339</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0034"><string-name><surname>Cochain</surname><given-names>C</given-names></string-name>, <string-name><surname>Ait‐Oufella</surname><given-names>H</given-names></string-name>, <string-name><surname>Zernecke</surname><given-names>A</given-names></string-name>. <article-title>Neutrophils promote atherosclerotic plaque destabilization in a mouse model of endotoxinaemia</article-title>. <source>Cardiovasc Res</source>. <year>2018</year>;<volume>114</volume>:<fpage>1573</fpage>‐<lpage>1574</lpage>.<pub-id pub-id-type="pmid">29992257</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0035"><string-name><surname>Chistiakov</surname><given-names>DA</given-names></string-name>, <string-name><surname>Bobryshev</surname><given-names>YV</given-names></string-name>, <string-name><surname>Orekhov</surname><given-names>AN</given-names></string-name>. <article-title>Neutrophil's weapons in atherosclerosis</article-title>. <source>Exp Mol Pathol</source>. <year>2015</year>;<volume>99</volume>:<fpage>663</fpage>‐<lpage>671</lpage>.<pub-id pub-id-type="pmid">26551083</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0036"><string-name><surname>Fülöp</surname><given-names>T</given-names></string-name>, <string-name><surname>Larbi</surname><given-names>A</given-names></string-name>, <string-name><surname>Witkowski</surname><given-names>JM</given-names></string-name>. <article-title>Human inflammaging</article-title>. <source>Gerontology</source>. <year>2019</year>;<volume>65</volume>:<fpage>495</fpage>‐<lpage>504</lpage>.<pub-id pub-id-type="pmid">31055573</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0037"><string-name><surname>Rajan</surname><given-names>MR</given-names></string-name>, <string-name><surname>Sotak</surname><given-names>M</given-names></string-name>, <string-name><surname>Barrenas</surname><given-names>F</given-names></string-name>, et al. <article-title>Comparative analysis of obesity‐related cardiometabolic and renal biomarkers in human plasma and serum</article-title>. <source>Sci Rep</source>. <year>2019</year>;<volume>9</volume>:<elocation-id>15385</elocation-id>.<pub-id pub-id-type="pmid">31659186</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0038"><string-name><surname>Xiong</surname><given-names>Y</given-names></string-name>, <string-name><surname>Brinkman</surname><given-names>CC</given-names></string-name>, <string-name><surname>Famulski</surname><given-names>KS</given-names></string-name>, et al. <article-title>A robust in vitro model for trans‐lymphatic endothelial migration</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>:<elocation-id>1633</elocation-id>.<pub-id pub-id-type="pmid">28487567</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0039"><string-name><surname>Gomez</surname><given-names>EA</given-names></string-name>, <string-name><surname>Colas</surname><given-names>RA</given-names></string-name>, <string-name><surname>Souza</surname><given-names>PR</given-names></string-name>, et al. <article-title>Blood pro‐resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis</article-title>. <source>Nat Commun</source>. <year>2020</year>;<volume>11</volume>:<elocation-id>5420</elocation-id>.<pub-id pub-id-type="pmid">33110080</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0040"><string-name><surname>Koenis</surname><given-names>DS</given-names></string-name>, <string-name><surname>Beegun</surname><given-names>I</given-names></string-name>, <string-name><surname>Jouvene</surname><given-names>CC</given-names></string-name>, et al. <article-title>Disrupted resolution mechanisms favor altered phagocyte responses in COVID‐19</article-title>. <source>Circ Res</source>. <year>2021</year>;<volume>129</volume>:<fpage>e54</fpage>‐<lpage>e71</lpage>.<pub-id pub-id-type="pmid">34238021</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0041"><string-name><surname>Gilroy</surname><given-names>DW</given-names></string-name>. <article-title>The role of aspirin‐triggered lipoxins in the mechanism of action of aspirin</article-title>. <source>Prostaglandins Leukot Essent Fatty Acids</source>. <year>2005</year>;<volume>73</volume>:<fpage>203</fpage>‐<lpage>210</lpage>.<pub-id pub-id-type="pmid">15978791</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0042"><string-name><surname>Elajami</surname><given-names>TK</given-names></string-name>, <string-name><surname>Colas</surname><given-names>RA</given-names></string-name>, <string-name><surname>Dalli</surname><given-names>J</given-names></string-name>, <string-name><surname>Chiang</surname><given-names>N</given-names></string-name>, <string-name><surname>Serhan</surname><given-names>CN</given-names></string-name>, <string-name><surname>Welty</surname><given-names>FK</given-names></string-name>. <article-title>Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling</article-title>. <source>FASEB J</source>. <year>2016</year>;<volume>30</volume>:<fpage>2792</fpage>‐<lpage>2801</lpage>.<pub-id pub-id-type="pmid">27121596</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0043"><string-name><surname>Birnbaum</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ye</surname><given-names>Y</given-names></string-name>, <string-name><surname>Lin</surname><given-names>Y</given-names></string-name>, et al. <article-title>Augmentation of myocardial production of 15‐epi‐lipoxin‐A<sub>4</sub> by pioglitazone and atorvastatin in the rat</article-title>. <source>Circulation</source>. <year>2006</year>;<volume>114</volume>:<fpage>929</fpage>‐<lpage>935</lpage>.<pub-id pub-id-type="pmid">16908763</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0044">
                <label>44</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0044"><string-name><surname>Nguyen</surname><given-names>GT</given-names></string-name>, <string-name><surname>Green</surname><given-names>ER</given-names></string-name>, <string-name><surname>Mecsas</surname><given-names>J</given-names></string-name>. <article-title>Neutrophils to the ROScue: mechanisms of NADPH oxidase activation and bacterial resistance</article-title>. <source>Front Cell Infect Microbiol</source>. <year>2017</year>;<volume>7</volume>:<elocation-id>373</elocation-id>.<pub-id pub-id-type="pmid">28890882</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0045">
                <label>45</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0045"><string-name><surname>Särndahl</surname><given-names>E</given-names></string-name>, <string-name><surname>Bergström</surname><given-names>I</given-names></string-name>, <string-name><surname>Brodin</surname><given-names>VP</given-names></string-name>, <string-name><surname>Nijm</surname><given-names>J</given-names></string-name>, <string-name><surname>Setterud</surname><given-names>HL</given-names></string-name>, <string-name><surname>Jonasson</surname><given-names>L</given-names></string-name>. <article-title>Neutrophil activation status in stable coronary artery disease</article-title>. <source>PLoS One</source>. <year>2007</year>;<volume>2</volume>:<elocation-id>e1056</elocation-id>.<pub-id pub-id-type="pmid">17957240</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0046">
                <label>46</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0046"><string-name><surname>Rademakers</surname><given-names>T</given-names></string-name>, <string-name><surname>van der Vorst</surname><given-names>EPC</given-names></string-name>, <string-name><surname>Daissormont</surname><given-names>ITMN</given-names></string-name>, et al. <article-title>Adventitial lymphatic capillary expansion impacts on plaque T cell accumulation in atherosclerosis</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>:<fpage>45263</fpage>.<pub-id pub-id-type="pmid">28349940</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0047">
                <label>47</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0047"><string-name><surname>Yeo</surname><given-names>KP</given-names></string-name>, <string-name><surname>Lim</surname><given-names>HY</given-names></string-name>, <string-name><surname>Angeli</surname><given-names>V</given-names></string-name>. <article-title>Leukocyte trafficking via lymphatic vessels in atherosclerosis</article-title>. <source>Cells</source>. <year>2021</year>;<volume>10</volume>:<elocation-id>1344</elocation-id>.<pub-id pub-id-type="pmid">34072313</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0048">
                <label>48</label>
                <mixed-citation publication-type="book" id="fsb222173-cit-0048"><string-name><surname>Kauffman</surname><given-names>D</given-names></string-name>. <source>Cardiovascular disease burden, deaths are rising around the world</source>. <publisher-name>American College of Cardiology</publisher-name>; <year>2020</year>.</mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0049">
                <label>49</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0049"><string-name><surname>Geovanini</surname><given-names>GR</given-names></string-name>, <string-name><surname>Libby</surname><given-names>P</given-names></string-name>. <article-title>Atherosclerosis and inflammation: overview and updates</article-title>. <source>Clin Sci (Lond)</source>. <year>2018</year>;<volume>132</volume>:<fpage>1243</fpage>‐<lpage>1252</lpage>.<pub-id pub-id-type="pmid">29930142</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0050">
                <label>50</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0050"><string-name><surname>Fava</surname><given-names>C</given-names></string-name>, <string-name><surname>Montagnana</surname><given-names>M</given-names></string-name>. <article-title>Atherosclerosis is an inflammatory disease which lacks a common anti‐inflammatory therapy: How human genetics can help to this issue. A narrative review</article-title>. <source>Front Pharmacol</source>. <year>2018</year>;<volume>9</volume>:<elocation-id>55</elocation-id>.<pub-id pub-id-type="pmid">29467655</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0051">
                <label>51</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0051"><string-name><surname>Ruparelia</surname><given-names>N</given-names></string-name>, <string-name><surname>Chai</surname><given-names>JT</given-names></string-name>, <string-name><surname>Fisher</surname><given-names>EA</given-names></string-name>, <string-name><surname>Choudhury</surname><given-names>RP</given-names></string-name>. <article-title>Inflammatory processes in cardiovascular disease: a route to targeted therapies</article-title>. <source>Nat Rev Cardiol</source>. <year>2017</year>;<volume>14</volume>:<fpage>133</fpage>‐<lpage>144</lpage>.<pub-id pub-id-type="pmid">27905474</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0052">
                <label>52</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0052"><string-name><surname>Ridker</surname><given-names>PM</given-names></string-name>, <string-name><surname>Everett</surname><given-names>BM</given-names></string-name>, <string-name><surname>Thuren</surname><given-names>T</given-names></string-name>, et al. <article-title>Antiinflammatory therapy with Canakinumab for atherosclerotic disease</article-title>. <source>N Engl J Med</source>. <year>2017</year>;<volume>377</volume>:<fpage>1119</fpage>‐<lpage>1131</lpage>.<pub-id pub-id-type="pmid">28845751</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0053">
                <label>53</label>
                <mixed-citation publication-type="book" id="fsb222173-cit-0053"><string-name><surname>Husten</surname><given-names>L</given-names></string-name>. <source>Experts caution on CANTOS and Canakinumab's future</source>. <publisher-name>MedPage Today</publisher-name>; <year>2017</year>.</mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0054">
                <label>54</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0054"><string-name><surname>Conte</surname><given-names>MS</given-names></string-name>, <string-name><surname>Desai</surname><given-names>TA</given-names></string-name>, <string-name><surname>Wu</surname><given-names>B</given-names></string-name>, <string-name><surname>Schaller</surname><given-names>M</given-names></string-name>, <string-name><surname>Werlin</surname><given-names>E</given-names></string-name>. <article-title>Pro‐resolving lipid mediators in vascular disease</article-title>. <source>J Clin Invest</source>. <year>2018</year>;<volume>128</volume>:<fpage>3727</fpage>‐<lpage>3735</lpage>.<pub-id pub-id-type="pmid">30168805</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0055">
                <label>55</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0055"><string-name><surname>Pirault</surname><given-names>J</given-names></string-name>, <string-name><surname>Bäck</surname><given-names>M</given-names></string-name>. <article-title>Lipoxin and resolvin receptors transducing the resolution of inflammation in cardiovascular disease</article-title>. <source>Front Pharmacol</source>. <year>2018</year>;<volume>9</volume>:<elocation-id>1273</elocation-id>.<pub-id pub-id-type="pmid">30487747</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0056">
                <label>56</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0056"><string-name><surname>Nascimento‐Silva</surname><given-names>V</given-names></string-name>, <string-name><surname>Arruda</surname><given-names>MA</given-names></string-name>, <string-name><surname>Barja‐Fidalgo</surname><given-names>C</given-names></string-name>, <string-name><surname>Fierro</surname><given-names>IM</given-names></string-name>. <article-title>Aspirin‐triggered lipoxin A<sub>4</sub> blocks reactive oxygen species generation in endothelial cells: a novel antioxidative mechanism</article-title>. <source>Thromb Haemost</source>. <year>2007</year>;<volume>97</volume>:<fpage>88</fpage>‐<lpage>98</lpage>.<pub-id pub-id-type="pmid">17200775</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0057">
                <label>57</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0057"><string-name><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name><surname>You</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>A</given-names></string-name>, et al. <article-title>Lipoxin A<sub>4</sub> attenuates uric acid‐activated, NADPH oxidase‐dependent oxidative stress by interfering with translocation of p47phox in human umbilical vein endothelial cells</article-title>. <source>Exp. Ther. Med</source>. <year>2020</year>;<volume>20</volume>:<fpage>1682</fpage>‐<lpage>1692</lpage>.<pub-id pub-id-type="pmid">32765680</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0058">
                <label>58</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0058"><string-name><surname>Zong</surname><given-names>L</given-names></string-name>, <string-name><surname>Li</surname><given-names>J</given-names></string-name>, <string-name><surname>Chen</surname><given-names>X</given-names></string-name>, et al. <article-title>Lipoxin A<sub>4</sub> attenuates cell invasion by inhibiting ROS/ERK/MMP pathway in pancreatic cancer</article-title>. <source>Oxid Med Cell Longev</source>. <year>2016</year>;<volume>2016</volume>:<elocation-id>6815727</elocation-id>.<pub-id pub-id-type="pmid">26649143</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0059">
                <label>59</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0059"><string-name><surname>Wu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhai</surname><given-names>H</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, et al. <article-title>Aspirin‐triggered lipoxin A<sub>4</sub> attenuates lipopolysaccharide‐induced intracellular ROS in BV2 microglia cells by inhibiting the function of NADPH oxidase</article-title>. <source>Neurochem Res</source>. <year>2012</year>;<volume>37</volume>:<fpage>1690</fpage>‐<lpage>1696</lpage>.<pub-id pub-id-type="pmid">22552474</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0060">
                <label>60</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0060"><string-name><surname>Soehnlein</surname><given-names>O</given-names></string-name>. <article-title>Multiple roles for neutrophils in atherosclerosis</article-title>. <source>Circ Res</source>. <year>2012</year>;<volume>110</volume>:<fpage>875</fpage>‐<lpage>888</lpage>.<pub-id pub-id-type="pmid">22427325</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0061">
                <label>61</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0061"><string-name><surname>Wenceslau</surname><given-names>CF</given-names></string-name>, <string-name><surname>McCarthy</surname><given-names>CG</given-names></string-name>, <string-name><surname>Szasz</surname><given-names>T</given-names></string-name>, <string-name><surname>Webb</surname><given-names>RC</given-names></string-name>. <article-title>Lipoxin A<sub>4</sub> mediates aortic contraction via RHOA/RHO kinase, endothelial dysfunction and reactive oxygen species</article-title>. <source>J Vasc Res</source>. <year>2014</year>;<volume>51</volume>:<fpage>407</fpage>‐<lpage>417</lpage>.<pub-id pub-id-type="pmid">25612650</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0062">
                <label>62</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0062"><string-name><surname>Basil</surname><given-names>MC</given-names></string-name>, <string-name><surname>Levy</surname><given-names>BD</given-names></string-name>. <article-title>Specialized pro‐resolving mediators: endogenous regulators of infection and inflammation</article-title>. <source>Nat Rev Immunol</source>. <year>2016</year>;<volume>16</volume>:<fpage>51</fpage>‐<lpage>67</lpage>.<pub-id pub-id-type="pmid">26688348</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0063">
                <label>63</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0063"><string-name><surname>Gavins</surname><given-names>FNE</given-names></string-name>. <article-title>Are formyl peptide receptors novel targets for therapeutic intervention in ischaemia–reperfusion injury?</article-title><source>Trends Pharmacol Sci</source>. <year>2010</year>;<volume>31</volume>:<fpage>266</fpage>‐<lpage>276</lpage>.<pub-id pub-id-type="pmid">20483490</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0064">
                <label>64</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0064"><string-name><surname>Cooray</surname><given-names>SN</given-names></string-name>, <string-name><surname>Gobbetti</surname><given-names>T</given-names></string-name>, <string-name><surname>Montero‐Melendez</surname><given-names>T</given-names></string-name>, et al. <article-title>Ligand‐specific conformational change of the G‐protein‐coupled receptor ALX/FPR2 determines proresolving functional responses</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2013</year>;<volume>110</volume>:<fpage>18232</fpage>‐<lpage>18237</lpage>.<pub-id pub-id-type="pmid">24108355</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0065">
                <label>65</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0065"><string-name><surname>Petri</surname><given-names>MH</given-names></string-name>, <string-name><surname>Thul</surname><given-names>S</given-names></string-name>, <string-name><surname>Andonova</surname><given-names>T</given-names></string-name>, et al. <article-title>Resolution of Inflammation through the lipoxin and ALX/FPR2 receptor pathway protects against abdominal aortic aneurysms</article-title>. <source>JACC Basic Transl Sci</source>. <year>2018</year>;<volume>3</volume>:<fpage>719</fpage>‐<lpage>727</lpage>.<pub-id pub-id-type="pmid">30623131</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0066">
                <label>66</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0066"><string-name><surname>Maderna</surname><given-names>P</given-names></string-name>, <string-name><surname>Cottell</surname><given-names>DC</given-names></string-name>, <string-name><surname>Toivonen</surname><given-names>T</given-names></string-name>, et al. <article-title>FPR2/ALX receptor expression and internalization are critical for lipoxin A<sub>4</sub> and annexin‐derived peptide‐stimulated phagocytosis</article-title>. <source>FASEB J</source>. <year>2010</year>;<volume>24</volume>:<fpage>4240</fpage>‐<lpage>4249</lpage>.<pub-id pub-id-type="pmid">20570963</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0067">
                <label>67</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0067"><string-name><surname>Perretti</surname><given-names>M</given-names></string-name>, <string-name><surname>Godson</surname><given-names>C</given-names></string-name>. <article-title>Formyl peptide receptor type 2 agonists to kick‐start resolution pharmacology</article-title>. <source>Br J Pharmacol</source>. <year>2020</year>;<volume>177</volume>:<fpage>4595</fpage>‐<lpage>4600</lpage>.<pub-id pub-id-type="pmid">32954491</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0068">
                <label>68</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0068"><string-name><surname>Dalli</surname><given-names>J</given-names></string-name>, <string-name><surname>Sanger</surname><given-names>JM</given-names></string-name>, <string-name><surname>Rodriguez</surname><given-names>AR</given-names></string-name>, <string-name><surname>Chiang</surname><given-names>N</given-names></string-name>, <string-name><surname>Spur</surname><given-names>BW</given-names></string-name>, <string-name><surname>Serhan</surname><given-names>CN</given-names></string-name>. <article-title>Identification and actions of a novel third maresin conjugate in tissue regeneration: MCTR3</article-title>. <source>PLoS One</source>. <year>2016</year>;<volume>11</volume>:<elocation-id>e0149319</elocation-id>.<pub-id pub-id-type="pmid">26881986</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0069">
                <label>69</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0069"><string-name><surname>Levy</surname><given-names>BD</given-names></string-name>. <article-title>Myocardial 15‐epi‐lipoxin A<sub>4</sub> generation provides a new mechanism for the immunomodulatory effects of statins and thiazolidinediones</article-title>. <source>Circulation</source>. <year>2006</year>;<volume>114</volume>:<fpage>873</fpage>‐<lpage>875</lpage>.<pub-id pub-id-type="pmid">16940203</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0070">
                <label>70</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0070"><string-name><surname>Zhou</surname><given-names>G</given-names></string-name>, <string-name><surname>Ge</surname><given-names>S</given-names></string-name>, <string-name><surname>Liu</surname><given-names>D</given-names></string-name>, et al. <article-title>Atorvastatin reduces plaque vulnerability in an atherosclerotic rabbit model by altering the 5‐lipoxygenase pathway</article-title>. <source>Cardiology</source>. <year>2010</year>;<volume>115</volume>:<fpage>221</fpage>‐<lpage>228</lpage>.<pub-id pub-id-type="pmid">20234134</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0071">
                <label>71</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0071"><string-name><surname>Serhan</surname><given-names>CN</given-names></string-name>. <article-title>Lipoxins and aspirin‐triggered 15‐epi‐lipoxins are the first lipid mediators of endogenous anti‐inflammation and resolution</article-title>. <source>Prostaglandins Leukot Essent Fatty Acids</source>. <year>2005</year>;<volume>73</volume>:<fpage>141</fpage>‐<lpage>162</lpage>.<pub-id pub-id-type="pmid">16005201</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0072">
                <label>72</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0072"><string-name><surname>Milasan</surname><given-names>A</given-names></string-name>, <string-name><surname>Smaani</surname><given-names>A</given-names></string-name>, <string-name><surname>Martel</surname><given-names>C</given-names></string-name>. <article-title>Early rescue of lymphatic function limits atherosclerosis progression in Ldlr(‐/‐) mice</article-title>. <source>Atherosclerosis</source>. <year>2019</year>;<volume>283</volume>:<fpage>106</fpage>‐<lpage>119</lpage>.<pub-id pub-id-type="pmid">30851674</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0073">
                <label>73</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0073"><string-name><surname>Llodrá</surname><given-names>J</given-names></string-name>, <string-name><surname>Angeli</surname><given-names>V</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name><surname>Trogan</surname><given-names>E</given-names></string-name>, <string-name><surname>Fisher</surname><given-names>EA</given-names></string-name>, <string-name><surname>Randolph</surname><given-names>GJ</given-names></string-name>. <article-title>Emigration of monocyte‐derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2004</year>;<volume>101</volume>:<fpage>11779</fpage>‐<lpage>11784</lpage>.<pub-id pub-id-type="pmid">15280540</pub-id></mixed-citation>
              </ref>
              <ref id="fsb222173-bib-0074">
                <label>74</label>
                <mixed-citation publication-type="journal" id="fsb222173-cit-0074"><string-name><surname>Kraft</surname><given-names>JD</given-names></string-name>, <string-name><surname>Blomgran</surname><given-names>R</given-names></string-name>, <string-name><surname>Lundgaard</surname><given-names>I</given-names></string-name>, <string-name><surname>Quiding‐Järbrink</surname><given-names>M</given-names></string-name>, <string-name><surname>Bromberg</surname><given-names>JS</given-names></string-name>, <string-name><surname>Börgeson</surname><given-names>E</given-names></string-name>. <article-title>Specialized pro‐resolving mediators and the lymphatic system</article-title>. <source>Int J Mol Sci</source>. <year>2021</year>;<volume>22</volume>:<elocation-id>2750</elocation-id>.<pub-id pub-id-type="pmid">33803130</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
